Diabetes & Metabolism Journal

Original Articles

Lifestyle and Behavioral Interventions
Influence of Fibroblast Growth Factor 21 on Delayed Glycemic Improvement Following Acute Exercise in Type 2 Diabetes Mellitus: Ying Zhang, Dan Liu, Yurun Lu, Piao Kang, Xinyu Liu, Qinyi Wang, Anran Chen, Di Cheng, Liang Wu, Qi Li, Xiaolin Wang, Yanli Li, Yaorui Ye, Jingyi Yang, Jiacheng Ni, Qichen Fang, Zhe Huang, Aimin Xu, Weiping Jia, Yong Wang, Guowang Xu, Huating Li; Received December 12, 2024 Accepted October 14, 2025 Published online March 25, 2026; DOI: https://doi.org/10.4093/dmj.2024.0814 [Epub ahead of print]

861 View
25 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Exercise positively influences glycemic control. Some individuals experience greater glycemic stability on the day after exercise, even without additional physical activity. However, the mechanisms underlying this delayed glycemic improvement remain unclear.
Methods
Seventy-one patients with type 2 diabetes mellitus were assigned to either a 60-minute exercise or resting group. Serum fibroblast growth factor 21 (FGF21) levels and untargeted metabolomic profiling were assessed at multiple time points before and after exercise. Interstitial glucose levels were monitored using continuous glucose monitoring system. FGF21 knockout mice and wildtype littermates on a high-fat diet, underwent a 3-week exercise intervention, and supplemented with recombinant mouse FGF21.
Results
Individuals exhibiting delayed glycemic improvement (responders) displayed a significantly stronger FGF21 response compared to non-responders. Baseline metabolites, including p-cresol sulfate and dimethylglycine, differed between responders and non-responders and were associated with the FGF21 response. Longitudinal time-series analyses revealed post-exercise differences in acylcarnitines, fatty acids, and complex lipids between responders and non-responders. Dynamic correlation and mediation analyses supported that FGF21 modulates delayed glycemic improvement via regulation of lipid metabolism. In vivo FGF21 knockout and rescue experiments demonstrated that FGF21 is necessary for these metabolic shifts and for the associated improvements in glucose tolerance and insulin sensitivity.
Conclusion
This study finds that the baseline metabolome is associated with the magnitude of the post-exercise FGF21 response, which influences delayed glycemic improvements through regulation of lipid metabolism pathways.

Pharmacotherapy
Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus: Inha Jung, Hangseok Choi, In Young Choi, Hyun Joo Cho, So Young Park, Da Young Lee, Ji A Seo, Nan Hee Kim, Ji Hee Yu; Diabetes Metab J. 2026;50(3):565-575. Published online November 24, 2025; DOI: https://doi.org/10.4093/dmj.2025.0681

1,389 View
42 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic control through insulinotropic and anorectic effects. However, the role of adipokines and appetite-related hormones in mediating the glycemic response remains unclear. This study evaluated changes in abdominal fat, food cravings, and circulating adipokines and gut hormones following dulaglutide treatment and identified predictors of glycemic improvement in type 2 diabetes mellitus (T2DM).
Methods
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly. Abdominal computed tomography, the General Food Cravings Questionnaire-Trait, and fasting levels of leptin, adiponectin, obestatin, ghrelin, and resistin were assessed at baseline and week 24. Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks. Multivariable regression analysis was performed to identify the factors associated with glycemic improvement.
Results
Among the 67 patients who completed the study, dulaglutide significantly reduced HbA1c, food cravings, leptin, and adiponectin levels. Obestatin levels increased modestly. Responders showed greater improvement in β-cell function and more pronounced reductions in food cravings. In the adjusted models, a decrease in leptin and an increase in obestatin were independently associated with HbA1c reduction, while decreased adiponectin was associated with poorer glycemic outcomes. Changes in body mass index or abdominal fat were not associated with glycemic improvement.
Conclusion
Dulaglutide improved glycemic control through mechanisms beyond weight reduction. Hormonal changes in leptin, adiponectin, and obestatin may help predict responses to GLP-1 RAs therapy.

Metabolic Risk/Epidemiology
Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study: Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim; Diabetes Metab J. 2025;49(6):1287-1297. Published online May 21, 2025; DOI: https://doi.org/10.4093/dmj.2024.0601

5,380 View
141 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
In this study, we aimed to determine the metabolic characteristics and changes in the early stages of young-onset type 2 diabetes mellitus (YOD) in Koreans.
Methods
From the Anam Diabetes Observational Study cohort (2017–2023), the characteristics of newly diagnosed YOD (<40 years of age, n=39) and later-onset (≥40 years of age) type 2 diabetes mellitus (LOD, n=178) were compared at diagnosis and 1 year later. All participants underwent an oral glucose tolerance test at diagnosis and annually thereafter. β-Cell function was determined using the disposition index (DI), calculated as the insulinogenic index×Matsuda insulin sensitivity index (ISI). Insulin sensitivity was determined using ISI and homeostasis model assessment of insulin resistance (HOMA2-IR).
Results
Mean (±standard deviation) age of individuals with YOD was 29.8±6.4 years, and 76.9% were male. YOD patients had higher body mass index (29.8 kg/m² vs. 27.2 kg/m², P=0.020), fat mass (30.5 kg vs. 24.1 kg, P=0.011), fatty liver index (65.4 vs. 49.2, P=0.005), and glycosylated hemoglobin (HbA1c) level at diagnosis (9.3% vs. 7.7%, P<0.001) compared with LOD patients. YOD patients exhibited lower insulin sensitivity (ISI: 2.79 vs. 3.26, P=0.008; HOMA2-IR: 2.72 vs. 1.83, P<0.001) and β-cell function (DI) at diagnosis (0.41 vs. 0.72, P=0.003) than LOD patients. Following 1 year of treatment, DI improved by 94% in YOD along with improvement in HbA1c; however, it was still significantly lower than that of LOD (0.64 vs. 0.90, P=0.017).
Conclusion
Individuals with YOD have unfavorable metabolic characteristics, substantially reduced insulin sensitivity, and decompensated β-cell function at disease onset, which persist even after treatment.

Citations

Citations to this article as recorded by

Compensated But Failing: Early β‐Cell Dysfunction Under Normoglycemia in Children and Adolescents With Overweight and Obesity
Paulina Correa‐Burrows, Estela Blanco, Raquel Burrows
Diabetes/Metabolism Research and Reviews.2026;[Epub] CrossRef

Pharmacotherapy
Initial Pharmacological Strategies in People with Early Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis: Jong Han Choi, Bo Kyung Koo, Ye Seul Yang, Se Hee Min, Jong Suk Park, Sang Youl Rhee, Hyun Jung Kim, Min Kyong Moon; Diabetes Metab J. 2025;49(6):1252-1261. Published online April 29, 2025; DOI: https://doi.org/10.4093/dmj.2024.0660

7,634 View
459 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Type 2 diabetes mellitus (T2DM) requires stringent glycemic control from an early stage to prevent complications. The most effective treatment regimen for early T2DM remains unclear. The study aimed to compare the efficacy and safety of monotherapies and combination therapies for early T2DM.
Methods
A systematic review and network meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Randomized controlled trials focused on glycemic control, body weight, and adverse events were included. The primary outcomes were changes in glycosylated hemoglobin (HbA1c) and odds of achieving the target HbA1c after 6 months.
Results
All combination therapies were more effective than monotherapy. Metformin+glucagon-like peptide-1 receptor agonists (GLP-1RA) (weighted mean difference [WMD] –1.50%; 95% confidence interval [CI] –2.04 to –0.96) and metformin+dipeptidyl peptidase-4 inhibitors (WMD –1.46%; 95% CI, –1.96 to –0.95) were the most effective for change in HbA1c. GLP-1RA and sodium- glucose cotransporter-2 inhibitors led to weight reduction. Apart from the increased risk of hypoglycemia with sulfonylureas, no significant differences in adverse events were observed across regimens.
Conclusion
Early combination therapy effectively improved glycemic control in patients with early T2DM without significantly increasing adverse risks. Future studies should explore new combinations, including potent GLP-1RA.

Citations

Citations to this article as recorded by

LASSBio-1986 as a Multifunctional Antidiabetic Lead: SGLT1/2 Docking, Redox–Inflammatory Modulation and Metabolic Benefits in C57BL/6 Mice
Landerson Lopes Pereira, Raimundo Rigoberto B. Xavier Filho, Gabriela Araújo Freire, Caio Bruno Rodrigues Martins, Maurício Gabriel Barros Perote, Cibelly Loryn Martins Campos, Manuel Carlos Serrazul Monteiro, Isabelle de Fátima Vieira Camelo Maia, Renata
International Journal of Molecular Sciences.2026; 27(2): 829. CrossRef

Technology/Device
Comparison of Real-Time and Intermittently-Scanned Continuous Glucose Monitoring for Glycemic Control in Type 1 Diabetes Mellitus: Nationwide Cohort Study: Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim; Diabetes Metab J. 2025;49(3):436-447. Published online February 27, 2025; DOI: https://doi.org/10.4093/dmj.2024.0160

8,054 View
251 Download
5 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study compares the association between real-time continuous glucose monitoring (rtCGM) and intermittently- scanned CGM (isCGM) and glycemic control in individuals with type 1 diabetes mellitus (T1DM) in a real-world setting.
Methods
Using data from the Korean National Health Insurance Service Cohort, individuals with T1DM managed by intensive insulin therapy were followed at 3-month intervals for 2 years after the initiation of CGM. The glycosylated hemoglobin (HbA1c) levels and coefficients of variation (CVs) of rtCGM and isCGM users were compared using independent two-sample t-test and a linear mixed model.
Results
The analyses considered 7,786 individuals (5,875 adults aged ≥19 years and 1,911 children and adolescents aged <19 years). Overall, a significant reduction in HbA1c level was observed after 3 months of CGM, and the effect was sustained for 2 years. The mean HbA1c level at baseline was higher in rtCGM users than in isCGM users (8.9%±2.7% vs. 8.6%±2.2%, P<0.001). However, from 3 to 24 months, rtCGM users had lower HbA1c levels than isCGM users at every time point (7.1%±1.2% vs. 7.5%±1.3% at 24 months, P<0.001 for all time points). In both adults and children, the greater reduction in HbA1c with rtCGM remained significant after adjusting for the baseline characteristics of the users. The CV also showed greater decrease with rtCGM than with isCGM.
Conclusion
In this large nationwide cohort study, the use of rtCGM was associated with a greater improvement in glycemic control, including HbA1c reduction, than the use of isCGM in both adults and children with T1DM.

Citations

Citations to this article as recorded by

EMERGING DIGITAL TECHNOLOGIES IN MONITORING ENDOCRINE DISORDERS: CONTINUOUS GLUCOSE MONITORING SYSTEMS AND ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME
Aleksandra Ćwirko-Godycka, Nikola Murawska, Michalina Chodór, Aleksandra Tomaszewska, Kinga Karczewska, Sonia Mojzyk, Maciej Kokoszka, Aleksandra Mierniczek, Natalia Dymel, Ryszard Feret
International Journal of Innovative Technologies in Social Science.2026;[Epub] CrossRef
Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison
Ji Eun Jun, Seohyun Kim, In‐Kyung Jeong, Jae Hyeon Kim
Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study
Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim
Diabetologia.2026;[Epub] CrossRef
Beneficial Analysis for Glucose Variability by Continuous Glucose Monitoring (CGM)
Sanae Mima, Hiroshi Bando, Akemi Tamura, Yukari Okino, Takumi Yamada, Yoshiyuki Abe
Asploro Journal of Biomedical and Clinical Case Reports.2025; 8(2): 193. CrossRef
Islet Tissue Macrophages in Immunity Homeostasis and Type 1 Diabetes
Yan Wang, Zhaoran Wang, Wenya Diao, Tong Shi, Jiahe Xu, Tiantian Deng, Chaoying Wen, Jienan Gu, Tingting Deng, Sixuan Wang, Cheng Xiao
Clinical Reviews in Allergy & Immunology.2025;[Epub] CrossRef
Continuous glucose monitoring in Korean pediatric patients with type 1 diabetes: current landscape and clinical implications
Hwa Young Kim, Jaehyun Kim
Clinical and Experimental Pediatrics.2025; 68(11): 842. CrossRef
Dispositivi indossabili per la gestione del diabete
Filippo CARLUCCI, Antonella TABUCCHI, Marcello FIORINI, Lucrezia GALASSO, Alessandro TERRENI
Biochimica Clinica.2025;[Epub] CrossRef
Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol
Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin
Endocrinology and Metabolism.2025;[Epub] CrossRef

Pathophysiology
Recent Glycemia Is a Major Determinant of β-Cell Function in Type 2 Diabetes Mellitus: Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim; Diabetes Metab J. 2024;48(6):1135-1146. Published online June 17, 2024; DOI: https://doi.org/10.4093/dmj.2023.0359

8,602 View
207 Download
7 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Progressive deterioration of β-cell function is a characteristic of type 2 diabetes mellitus (T2DM). We aimed to investigate the relative contributions of clinical factors to β-cell function in T2DM.
Methods
In a T2DM cohort of 470 adults (disease duration 0 to 41 years), β-cell function was estimated using insulinogenic index (IGI), disposition index (DI), oral disposition index (DIO), and homeostasis model assessment of β-cell function (HOMA-B) derived from a 75 g oral glucose tolerance test (OGTT). The relative contributions of age, sex, disease duration, body mass index, glycosylated hemoglobin (HbA1c) levels (at the time of the OGTT), area under the curve of HbA1c over time (HbA1c AUC), coefficient of variation in HbA1c (HbA1c CV), and antidiabetic agents use were compared by standardized regression coefficients. Longitudinal analyses of these indices were also performed.
Results
IGI, DI, DI_O, and HOMA-B declined over time (P<0.001 for all). Notably, HbA1c was the most significant factor affecting IGI, DI, DIO, and HOMA-B in the multivariable regression analysis. Compared with HbA1c ≥9%, DI was 1.9-, 2.5-, 3.7-, and 5.5-fold higher in HbA1c of 8%–<9%, 7%–<8%, 6%–<7%, and <6%, respectively, after adjusting for confounding factors (P<0.001). Conversely, β-cell function was not affected by the type or duration of antidiabetic agents, HbA1c AUC, or HbA1c CV. The trajectories of the IGI, DI, DIO, and HOMA-B mirrored those of HbA1c.
Conclusion
β-Cell function declines over time; however, it is flexible, being largely affected by recent glycemia in T2DM.

Citations

Citations to this article as recorded by

An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
Zhuolin Zhou, Nan Gao, Jiaojiao Liu, Xuerong Ma, Zhijuan Ge, Cheng Ji
Diabetes, Obesity and Metabolism.2026; 28(1): 122. CrossRef
Machine learning and engagement insights for personalized blood glucose management
Inbar Breuer Asher, David L. Horwitz, Omar Manejwala, Yifat Fundoiano-Hershcovitz
Frontiers in Digital Health.2026;[Epub] CrossRef
Redefining β-Cell Function in Type 2 Diabetes Mellitus: From Comprehensive Assessment to Precision Medicine
YongKyung Kim, Joon Ha, Jun Sung Moon
Diabetes & Metabolism Journal.2026; 50(2): 235. CrossRef
Compensated But Failing: Early β‐Cell Dysfunction Under Normoglycemia in Children and Adolescents With Overweight and Obesity
Paulina Correa‐Burrows, Estela Blanco, Raquel Burrows
Diabetes/Metabolism Research and Reviews.2026;[Epub] CrossRef
Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial
Minyoung Lee, Sukchul Hong, Yongin Cho, Hyungjin Rhee, Min Heui Yu, Jaehyun Bae, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
BMC Medicine.2025;[Epub] CrossRef
Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2025; 49(6): 1287. CrossRef
Unlocking Gut-Driven Metabolic Repair: The Role of Glucomannan Porang (Amorphophallus muelleri Blume) in Insulin Resistance and Short-Chain Fatty Acid Modulation in a Type 2 Diabetes Mellitus Rat Model
Azizah H. Safitri, Rahmata A. Sayyida, Eni Widayati, Nurina Tyagita
Tropical Journal of Natural Product Research.2025;[Epub] CrossRef
The Importance of Treating Hyperglycemia in β-Cell Dysfunction of Type 2 Diabetes Mellitus
Arim Choi, Kyung-Soo Kim
Diabetes & Metabolism Journal.2024; 48(6): 1056. CrossRef

Complications
Glycemic Control and Retinal Microvascular Changes in Type 2 Diabetes Mellitus Patients without Clinical Retinopathy: Kangmin Lee, Ga Hye Lee, Seung Eun Lee, Jee Myung Yang, Kunho Bae; Diabetes Metab J. 2024;48(5):983-992. Published online March 13, 2024; DOI: https://doi.org/10.4093/dmj.2023.0149

7,532 View
263 Download
8 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To investigate the association of glycemic control and retinal microvascular changes in patients with type 2 diabetes mellitus (T2DM) without diabetic retinopathy (DR).
Methods
This retrospective, observational, cohort study included patients with T2DM without DR. The patients were categorized into intensive control (IC; mean glycosylated hemoglobin [HbA1c] ≤7.0%) and moderate control (MC; mean HbA1c >7.0%) groups. Optical coherence tomography (OCT) and swept-source OCT angiography (OCTA) image parameters were compared between three groups, including healthy controls.
Results
In total, 259 eyes of 259 participants (88 IC, 81 MC, and 90 controls) were included. The foveal avascular zone area was significantly larger in the MC group than IC and control groups (all P<0.05). The IC group had lower vessel density in the superficial retinal layer and deep retinal layer than the controls (all P<0.05). The choriocapillaris (CC) flow deficit (FD) was significantly greater in the MC group than in the IC and control groups (18.2%, 16.7%, and 14.2%, respectively; all P<0.01). In multivariate regression analysis, CC-FD was associated with the mean HbA1c level (P=0.008). There were no significant differences in OCT parameters among the groups.
Conclusion
OCTA revealed that early CC impairment is associated with HbA1c levels; the CC changes precede clinically apparent DR. The OCTA parameters differed among the groups according to the degree of glycemic control. Our results suggest that microvascular changes precede DR and are closely related to glycemic control.

Citations

Citations to this article as recorded by

Quantitative evaluation of the topographical maps of three-dimensional choroidal vascularity index in gestational diabetes mellitus: a cross-sectional observational study
Ligang Jiang, Yimei Ji, Xin Jiang, Yune Zhao
BMC Pregnancy and Childbirth.2026;[Epub] CrossRef
Impact of Vascular Risk Factors on Longitudinal Changes in Diabetic Macular Edema After Intravitreal Therapy
Carmen Alba-Linero, José Coín Ruiz, Marta Mérida Luque, Javier Espíldora-Hernández, Mario Gutiérrez Bedmar
Diabetology.2026; 7(4): 65. CrossRef
Correlation of Glycemic Risk Index with Retinal Structure and Blood Flow in Patients without Diabetic Retinopathy
丁元曹
Advances in Clinical Medicine.2026; 16(04): 4184. CrossRef
Flow and ischemic changes in retina and choroid across diabetic retinopathy spectrum: a SS-OCTA study
Qianhui Yang, Kelvin Y. C. Teo, Yueheng Hong, Bingyao Tan, Leopold Schmetterer, Chui Ming Gemmy Cheung, Tien Yin Wong, Gavin Tan Siew Wei
Eye.2025; 39(8): 1631. CrossRef
Postprandial C-Peptide to Glucose Ratio as a Promising Systemic Marker of Diabetic Retinopathy in Type 2 Diabetes
Zhaoxia Zheng, Nianen Liu, Yue Zhang, Xiaoya Gu, Hui Li, Xiaobing Yu
Translational Vision Science & Technology.2025; 14(7): 27. CrossRef
The Correlation Between Macular Vessel Density and Its Clinical Parameters in Diabetes Mellitus Type 2
Nadia Dewi, Muhammad Arfan, Herisa Rahmasari, Mutiara Putri, Rulli Rosandi
Clinical Ophthalmology.2025; Volume 19: 3113. CrossRef
Comment on: “Risk factors and incidence of macular edema in eyes with retinal vein occlusion after uneventful cataract surgery: The MEVO study”
Xianmei Zhang, Jing Chen
Indian Journal of Ophthalmology.2025; 73(11): 1698. CrossRef
Prevalence and determinants of comorbidities among patients with type 2 diabetes mellitus in Nepal: a cross-sectional study
Nitendra Kumar Chaurasia, Md Mothashin, Md Golam Hossain
BMC Endocrine Disorders.2025;[Epub] CrossRef

Drug/Regimen
Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus: Shinae Kang, Yu-Bae Ahn, Tae Keun Oh, Won-Young Lee, Sung Wan Chun, Boram Bae, Amine Dahaoui, Jin Sook Jeong, Sungeun Jung, Hak Chul Jang; Diabetes Metab J. 2024;48(5):929-936. Published online February 27, 2024; DOI: https://doi.org/10.4093/dmj.2023.0297

8,219 View
292 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the real-world efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM), whose insulin treatment was switched to IDegAsp.
Methods
This was a multicenter, retrospective, observational study comprising two 26-week treatment periods, before and after switching to IDegAsp, respectively. Korean adults with uncontrolled T2DM treated with basal or premix insulin (±oral antidiabetic drugs) were enrolled. The primary objective was to compare the degree of glycosylated hemoglobin (HbA1c) change in each 26-week observation period. The analyses included changes in HbA1c, fasting plasma glucose (FPG), body weight, proportion of participants achieving HbA1c <7.0%, hypoglycemic events, and total daily insulin dose (ClinicalTrials.gov, number NCT04656106).
Results
In total, 196 adults (mean age, 65.95 years; mean T2DM duration, 18.99 years) were analyzed. The change in both HbA1c and FPG were significantly different between the pre-switching and the post-switching period (0.28% vs. –0.51%, P<0.001; 5.21 mg/dL vs. –23.10 mg/dL, P=0.005), respectively. After switching, the rate of achieving HbA1c <7.0% was significantly improved (5.10% at baseline vs. 11.22% with IDegAsp, P=0.012). No significant differences (before vs. after switching) were observed in body weight change, and total daily insulin dose. The rates of overall and severe hypoglycemia were similar in the two periods.
Conclusion
In real-world clinical practice in Korea, the change of insulin regimen to IDegAsp was associated with an improvement in glycemic control without increase of hypoglycemia, supporting the use of IDegAsp for patients with T2DM uncontrolled with basal or premix insulin.

Citations

Citations to this article as recorded by

Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes
Sezin Dogan Çakır, Hatice Deniz Yücel, Zeynep Akgül Kızılçay, Mine Adaş
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Efficacy and safety of insulin degludec/aspart in patients with type 2 and type 1 diabetes mellitus: real-world evidence from Indonesia
Hendra Zufry, Krishna Wardhana Sucipto, Agustia Sukri Ekadamayanti, Qanita Iqbal
Frontiers in Endocrinology.2025;[Epub] CrossRef
Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing
Yiming Wu, Junqing Zhang, Ang Li
Diabetes Therapy.2024; 15(12): 2515. CrossRef

Metabolic Risk/Epidemiology
Glycemic Control Is Associated with Histological Findings of Nonalcoholic Fatty Liver Disease: Teruki Miyake, Shinya Furukawa, Bunzo Matsuura, Osamu Yoshida, Masumi Miyazaki, Akihito Shiomi, Ayumi Kanamoto, Hironobu Nakaguchi, Yoshiko Nakamura, Yusuke Imai, Mitsuhito Koizumi, Takao Watanabe, Yasunori Yamamoto, Yohei Koizumi, Yoshio Tokumoto, Masashi Hirooka, Teru Kumagi, Eiji Takesita, Yoshio Ikeda, Masanori Abe, Yoichi Hiasa; Diabetes Metab J. 2024;48(3):440-448. Published online February 2, 2024; DOI: https://doi.org/10.4093/dmj.2023.0200

9,469 View
339 Download
11 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Poor lifestyle habits may worsen nonalcoholic fatty liver disease (NAFLD), with progression to nonalcoholic steatohepatitis (NASH) and cirrhosis. This study investigated the association between glycemic control status and hepatic histological findings to elucidate the effect of glycemic control on NAFLD.
Methods
This observational study included 331 patients diagnosed with NAFLD by liver biopsy. Effects of the glycemic control status on histological findings of NAFLD were evaluated by comparing the following four glycemic status groups defined by the glycosylated hemoglobin (HbA1c) level at the time of NAFLD diagnosis: ≤5.4%, 5.5%–6.4%, 6.5%–7.4%, and ≥7.5%.
Results
Compared with the lowest HbA1c group (≤5.4%), the higher HbA1c groups (5.5%–6.4%, 6.5%–7.4%, and ≥7.5%) were associated with advanced liver fibrosis and high NAFLD activity score (NAS). On multivariate analysis, an HbA1c level of 6.5%– 7.4% group was significantly associated with advanced fibrosis compared with the lowest HbA1c group after adjusting for age, sex, hemoglobin, alanine aminotransferase, and creatinine levels. When further controlling for body mass index and uric acid, total cholesterol, and triglyceride levels, the higher HbA1c groups were significantly associated with advanced fibrosis compared with the lowest HbA1c group. On the other hand, compared with the lowest HbA1c group, the higher HbA1c groups were also associated with a high NAS in both multivariate analyses.
Conclusion
Glycemic control is associated with NAFLD exacerbation, with even a mild deterioration in glycemic control, especially a HbA1c level of 6.5%–7.4%, contributing to NAFLD progression.

Citations

Citations to this article as recorded by

Effect of remnant cholesterol on the onset of diabetes mellitus
Teruki Miyake, Shinya Furukawa, Ayumi Kanamoto, Osamu Yoshida, Yoshimasa Murakami, Masumi Miyazaki, Akihito Shiomi, Sho Ishikawa, Yuki Numata, Hironobu Nakaguchi, Yoshiko Nakamura, Mitsuhito Koizumi, Takao Watanabe, Yasunori Yamamoto, Hirohito Mori, Eiji
Journal of Diabetes Investigation.2026; 17(1): 120. CrossRef
Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis
Rafael Dos Santos Borges, Eliabe S. Abreu, Giovanni Gosch Berton, Luiza Haikal de Paula, Ana Flávia Conegundes, Jefferson Manoel Borges Martins, Marcelo Albuquerque Barbosa Martins, Aladdin S. Dahbour, Matheus Vanzin Fernandes, Manal F. Abdelmalek
JHEP Reports.2026; 8(4): 101708. CrossRef
Association of nitrogen dioxide with non-alcoholic fatty liver disease in Chinese rural older adults: The mediating role of fasting plasma glucose
Yuantao Zhang, Xianglong Liu, Yunkai Hu, Xuqiu Cheng, Wenyuan Liu, Ziwei Tian, Yan Zhang, Guimei Chen, Bing Hu, Changliu Liang, Chunmei Liang, Fangbiao Tao, Linsheng Yang
Environmental Research.2026; 290: 123518. CrossRef
Metabolic biomarkers add little to diagnostic performance of FIB-4 in MASLD
Sofia Ullman, Hannes Hegmar, Johan Vessby, Patrik Nasr, Stergios Kechagias, Nils Nyhlin, Åsa Danielsson Borssén, Mattias Ekstedt, Hannes Hagström
Scandinavian Journal of Gastroenterology.2026; 61(3): 340. CrossRef
Effect of body mass index change on the development of diabetes mellitus
Masahiro Okano, Teruki Miyake, Shinya Furukawa, Osamu Yoshida, Yoshimasa Murakami, Ayumi Kanamoto, Masumi Miyazaki, Akihito Shiomi, Hironobu Nakaguchi, Yasunori Yamamoto, Yoshio Tokumoto, Masashi Hirooka, Teru Kumagi, Eiji Takesita, Yoshio Ikeda, Masanori
Endocrine Journal.2026; 73(2): 183. CrossRef
Effect of common diabetes medications on metabolic dysfunction-associated steatotic liver disease as measured by transient elastography and other metabolic parameters: A systematic review
Kathryn Thompson, William Breaux, Lesley S. Miller, John Nemeth, Sarah Koumtouzoua, Natasha Travis
Clinics and Research in Hepatology and Gastroenterology.2026; 50(3): 102784. CrossRef
Multidisciplinary Management of Metabolic Dysfunction‐Associated Steatohepatitis: A Single‐Centre European Experience
Maria Antentas, Idoia Genua, Berta Ferández‐Camins, Elisabeth Pérez‐Chust, Francesca Mayolas‐Mateu, Eva Román, Maria Poca, German Soriano, Juan Antonio Arroyo‐Díaz, Marina Idalia Rojo‐López, Dídac Mauricio
Liver International Communications.2026;[Epub] CrossRef
The association between glycemic state, R factor and Steatosis-Associated Fibrosis Estimator score in advanced liver fibrosis in patients with diabetes mellitus
Mohammadjavad Sotoudeheian, Seyed-Mohamad-Sadegh Mirahmadi, Reza Azarbad
Obesity Medicine.2025; 53: 100575. CrossRef
Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020
Ting Xu, Weifang Zhu
Diabetes Research and Clinical Practice.2025; 227: 112418. CrossRef
Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
Akihito Shiomi, Teruki Miyake, Shinya Furukawa, Bunzo Matsuura, Osamu Yoshida, Takao Watanabe, Ayumi Kanamoto, Masumi Miyazaki, Hironobu Nakaguchi, Yoshio Tokumoto, Masashi Hirooka, Masanori Abe, Yoichi Hiasa
Hepatology Research.2024; 54(11): 1016. CrossRef
Overweight Impacts Histological Disease Activity of De Novo Metabolic Dysfunction‐Associated Steatotic Liver Disease After Liver Transplantation
Alejandro Campos‐Murguia, Lea Guetzlaff, Emily Bosselmann, Bastian Engel, Björn Hartleben, Heiner Wedemeyer, Elmar Jaeckel, Richard Taubert, Katharina Luise Hupa‐Breier
Clinical Transplantation.2024;[Epub] CrossRef

Reviews

Cardiovascular Risk/Epidemiology
Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus: Takayoshi Sasako, Toshimasa Yamauchi, Kohjiro Ueki; Diabetes Metab J. 2023;47(2):185-197. Published online January 12, 2023; DOI: https://doi.org/10.4093/dmj.2022.0325

15,770 View
558 Download
20 Web of Science
21 Crossref

Abstract PDF PubReader ePub

In the management of diabetes mellitus, one of the most important goals is to prevent its micro- and macrovascular complications, and to that end, multifactorial intervention is widely recommended. Intensified multifactorial intervention with pharmacotherapy for associated risk factors, alongside lifestyle modification, was first shown to be efficacious in patients with microalbuminuria (Steno-2 study), then in those with less advanced microvascular complications (the Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care [ADDITION]-Europe and the Japan Diabetes Optimal Treatment study for 3 major risk factors of cardiovascular diseases [J-DOIT3]), and in those with advanced microvascular complications (the Nephropathy In Diabetes-Type 2 [NID-2] study and Diabetic Nephropathy Remission and Regression Team Trial in Japan [DNETT-Japan]). Thus far, multifactorial intervention led to a reduction in cardiovascular and renal events, albeit not necessarily significant. It should be noted that not only baseline characteristics but also the control status of the risk factors and event rates during intervention among the patients widely varied from one trial to the next. Further evidence is needed for the efficacy of multifactorial intervention in a longer duration and in younger or elderly patients. Moreover, now that new classes of antidiabetic drugs are available, it should be addressed whether strict and safe glycemic control, alongside control of other risk factors, could lead to further risk reductions in micro- and macrovascular complications, thereby decreasing all-cause mortality in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

The gaps between the guidelines definitions and routine of care adopted in primary health care regarding diabetes kidney disease: a real-life study
Silvia Ferreira Bortoto, Jacira Xavier de Carvalho, Mozania Reis de Matos, Cristiane das Graças Dias Cavalcante, Elenilda Almeida Silva Andrade, Márcia Silva Queiroz
Journal of Public Health.2026; 34(5): 1131. CrossRef
Biomedical outcomes and cardiovascular risks in Chinese adults with type 2 diabetes in the metabolic management center program: A longitudinal comparative study
Zhanpeng He, Hui Cheng, Zhihui Jia, Zimin Niu, Yu Ting Li, Wenyong Huang, Vivian Yawei Guo, Zhiran Su, Yao Jie Xie, Jie Shen, Harry HX Wang
Journal of Diabetes Investigation.2025; 16(5): 884. CrossRef
Thiamine and METTL14 in Diabetes Management with Intensive Insulin Therapy
Miaoguan Peng, Yingying Zhang, Xiaoshi Weng, Jianfeng Wu, Taizhen Luo, Yanmei Dong, Shiyun Wen, Naifeng Liang, Liangying Zhong, Yaojie Zhai, Yijuan Xie, Yingjun Xie, Yuyi Chen
Biomedicines.2025; 13(4): 980. CrossRef
Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative Care
Philip Kam-Tao Li, Michael Cheung, Kai-Ming Chow, Maria Kwan Wa Leung, Lee-Ling Lim, Juliana N.M. Lui, Andrea O.Y. Luk, Jo-Anne Manski-Nankervis, Samuel Seidu, Nikhil Tandon, Adrian Liew, Peter Lin, Fei Chau Pang, Na Tian, Kohjiro Ueki, Martin C.S. Wong,
Kidney International Reports.2025; 10(8): 2551. CrossRef
Comparative Pharmacological and Pharmaceutical Perspectives on Antidiabetic Therapies in Humans, Dogs, and Cats
Iljin Kim, Jang-Hyuk Yun
Pharmaceutics.2025; 17(9): 1098. CrossRef
Diabetic retinopathy as a sentinel of systemic vascular dysfunction: Shared molecular mechanisms with cardiovascular disease
Ting Wang, Hongyu Li, Chuyao Wang, Xiuyun Li, Aijun Deng, Xinwei Jiao
Experimental Eye Research.2025; 261: 110644. CrossRef
Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes
Takayoshi Sasako, Kohjiro Ueki, Kengo Miyoshi, Kana Miyake, Tomohisa Aoyama, Yukiko Okazaki, Naoki Ishizuka, Toshimasa Yamauchi, Mitsuhiko Noda, Takashi Kadowaki, Masakazu Haneda, Yasunori Iwashima, Mizuho Okada, Toshihiro Suda, Naoki Tamasawa, Makoto Dai
JAMA Ophthalmology.2025; 143(12): 989. CrossRef
Treatment of Type 2 Diabetes: A Comprehensive Review of Recent Improvements, Therapeutic Strategies, Challenges, and Future Perspectives
Tawhidul Islam, Nazim Uddin
EMJ Diabetes.2025; : 72. CrossRef
Exploring mechanisms underlying diabetes comorbidities and strategies to prevent vascular complications
Takayoshi Sasako
Diabetology International.2024; 15(1): 34. CrossRef
Targeting ERS-mitophagy in hippocampal neurons to explore the improvement of memory by tea polyphenols in aged type 2 diabetic rats
Wenjuan Feng, Chenhui Lv, Le Cheng, Xin Song, Xuemin Li, Haoran Xie, Shuangzhi Chen, Xi Wang, Lushan Xue, Cheng Zhang, Jie Kou, Lili Wang, Haifeng Zhao
Free Radical Biology and Medicine.2024; 213: 293. CrossRef
Risk of Dementia Among Patients With Diabetes in a Multidisciplinary, Primary Care Management Program
Kailu Wang, Shi Zhao, Eric Kam-Pui Lee, Susan Zi-May Yau, Yushan Wu, Chi-Tim Hung, Eng-Kiong Yeoh
JAMA Network Open.2024; 7(2): e2355733. CrossRef
Causes of In-Hospital Death and Pharmaceutical Associations with Age of Death during a 10-Year Period (2011–2020) in Individuals with and without Diabetes at a Japanese Community General Hospital
Minae Hosoki, Taiki Hori, Yousuke Kaneko, Kensuke Mori, Saya Yasui, Seijiro Tsuji, Hiroki Yamagami, Saki Kawata, Tomoyo Hara, Shiho Masuda, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsur
Journal of Clinical Medicine.2024; 13(5): 1283. CrossRef
External validation of a minimal-resource model to predict reduced estimated glomerular filtration rate in people with type 2 diabetes without diagnosis of chronic kidney disease in Mexico: a comparison between country-level and regional performance
Camilla Sammut-Powell, Rose Sisk, Ruben Silva-Tinoco, Gustavo de la Pena, Paloma Almeda-Valdes, Sonia Citlali Juarez Comboni, Susana Goncalves, Rory Cameron
Frontiers in Endocrinology.2024;[Epub] CrossRef
Gut Microbiota Targeted Approach by Natural Products in Diabetes Management: An Overview
Priyanka Sati, Praveen Dhyani, Eshita Sharma, Dharam Chand Attri, Arvind Jantwal, Rajni Devi, Daniela Calina, Javad Sharifi-Rad
Current Nutrition Reports.2024; 13(2): 166. CrossRef
Lipids as potential mediators linking body mass index to diabetes: evidence from a mediation analysis based on the NAGALA cohort
Song Lu, Qun Wang, Hengcheng Lu, Maobin Kuang, Min Zhang, Guotai Sheng, Yang Zou, Xiaoping Peng
BMC Endocrine Disorders.2024;[Epub] CrossRef
Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics
Shuai Li, Zilong Song, Chunxiang Fan, Weiwei Zhang, Tianyi Ma, Xu Li, Qi Zhang, Ming Zhao, Tianfei Yu, Shanshan Li
Biochemical Pharmacology.2024; 225: 116306. CrossRef
Exploring mechanisms of insulin action and strategies to treat diabetes
Takayoshi Sasako
Endocrine Journal.2024; 71(7): 651. CrossRef
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Alfredo Caturano, Raffaele Galiero, Maria Rocco, Giuseppina Tagliaferri, Alessia Piacevole, Davide Nilo, Giovanni Di Lorenzo, Celestino Sardu, Erica Vetrano, Marcellino Monda, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso
Biomedicines.2024; 12(9): 2039. CrossRef
Recent Glycemia Is a Major Determinant of β-Cell Function in Type 2 Diabetes Mellitus
Ji Yoon Kim, Jiyoon Lee, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2024; 48(6): 1135. CrossRef
Cardiovascular Risk Reduction in Type 2 Diabetes: Further Insights into the Power of Weight Loss and Exercise
Seung-Hwan Lee
Endocrinology and Metabolism.2023; 38(3): 302. CrossRef
Sarcopenia: Loss of mighty armor against frailty and aging
Takayoshi Sasako, Kohjiro Ueki
Journal of Diabetes Investigation.2023; 14(10): 1145. CrossRef

Guideline/Fact Sheet
Comprehensive Understanding for Application in Korean Patients with Type 2 Diabetes Mellitus of the Consensus Statement on Carbohydrate-Restricted Diets by Korean Diabetes Association, Korean Society for the Study of Obesity, and Korean Society of Hypertension: Jong Han Choi, Jee-Hyun Kang, Suk Chon; Diabetes Metab J. 2022;46(3):377-390. Published online May 25, 2022; DOI: https://doi.org/10.4093/dmj.2022.0051

11,745 View
308 Download
4 Web of Science
4 Crossref

Abstract PDF PubReader ePub

The Joint Committee of the Korean Diabetes Association, the Korean Society for the Study of Obesity, and the Korean Society of Hypertension announced a consensus statement on carbohydrate-restricted diets and intermittent fasting, representing an emerging and popular dietary pattern. In this statement, we recommend moderately-low-carbohydrate or low-carbohydrate diets, not a very-low-carbohydrate diet, for patients with type 2 diabetes mellitus. These diets can be considered a dietary regimen to improve glycemic control and reduce body weight in adults with type 2 diabetes mellitus. This review provides the detailed results of a meta-analysis and systematic literature review on the potential harms and benefits of carbohydrate-restricted diets in patients with diabetes. We expect that this review will help experts and patients by fostering an in-depth understanding and appropriate application of carbohydrate-restricted diets in the comprehensive management of diabetes.

Citations

Citations to this article as recorded by

The effects of low-carbohydrate diet on glucose and lipid metabolism in overweight or obese patients with T2DM: a meta-analysis of randomized controlled trials
Wende Tian, Shuyu Cao, Yongxin Guan, Zihao Zhang, Qiyu Liu, Jianqing Ju, Ruixi Xi, Ruina Bai
Frontiers in Nutrition.2025;[Epub] CrossRef
Efficacy of convenience meal-type foods designed for diabetes in the management of metabolic syndrome based on a 3-week trial
Do Gyeong Lee, In Gyeong Kang, Tae Seok Kim, Yun Ahn, Sang Yun Lee, Hye Jin Ahn, Yoo Kyoung Park
Nutrition.2024; 118: 112287. CrossRef
Long-Term Results of a Digital Diabetes Self-Management and Education Support Program Among Adults With Type 2 Diabetes: A Retrospective Cohort Study
Ashley Berthoumieux, Sarah Linke, Melinda Merry, Alison Megliola, Jessie Juusola, Jenna Napoleone
The Science of Diabetes Self-Management and Care.2024; 50(1): 19. CrossRef
Medical nutrition therapy for diabetes mellitus
Suk Chon
Journal of the Korean Medical Association.2023; 66(7): 421. CrossRef

Original Articles

Drug/Regimen
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study: Hae Jin Kim, In Kyung Jeong, Kyu Yeon Hur, Soo-Kyung Kim, Jung Hyun Noh, Sung Wan Chun, Eun Seok Kang, Eun-Jung Rhee, Sung Hee Choi; Diabetes Metab J. 2022;46(5):689-700. Published online March 17, 2022; DOI: https://doi.org/10.4093/dmj.2021.0183

11,630 View
432 Download
5 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly controlled T2DM patients with drug-naïve or metformin failure.
Methods
In this three-arm, multicenter, open-label, randomized, controlled trial, poorly controlled T2DM patients were randomized to receive GLIM (n=35), ALO (n=31), or ALO-PIO (n=33) therapy for 24 weeks. The primary endpoint was change in the mean glycosylated hemoglobin (HbA1c) levels at week 24 from baseline. Secondary endpoints were changes in HbA1c level at week 12 from baseline, fasting plasma glucose (FPG) levels, lipid profiles at weeks 12 and 24, and parameters of glycemic variability, assessed by continuous glucose monitoring for 24 weeks.
Results
At weeks 12 and 24, the ALO-PIO group showed significant reduction in HbA1c levels compared to the ALO group (–0.96%±0.17% vs. –0.37%±0.17% at week 12; –1.13%±0.19% vs. –0.18%±0.2% at week 24). The ALO-PIO therapy caused greater reduction in FPG levels and significant increase in high-density lipoprotein cholesterol levels at weeks 12 and 24 than the ALO therapy. Compared to low-dose GLIM therapy, ALO-PIO therapy showed greater improvement in glycemic variability. The adverse events were similar among the three arms.
Conclusion
ALO-PIO combination therapy during the early period exerts better glycemic control than ALO monotherapy and excellency in glycemic variability than low-dose sulfonylurea therapy in uncontrolled, drug-naïve or metformin failed T2DM patients.

Citations

Citations to this article as recorded by

Assessment of the effectiveness and safety of fixed-dose combination of alogliptin and pioglitazone in real clinical practice: results of the PROsperity study
M. V. Shestakova, M. I. Kharakhulakh, Y. A. Belolipetsky
Diabetes mellitus.2025; 28(2): 198. CrossRef
Fixed-dose combinations of hypoglycemic drugs: potential of alogliptin/pioglitazone in type 2 diabetes mellitus: a review
Olga I. Butranova, Sergey K. Zyryanov, Anna R. Melnikova, Anastasia E. Matsepuro
Terapevticheskii arkhiv.2025; 97(8): 735. CrossRef
Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies
Youngwoo Jang, Eun-Jung Rhee, Sung Hee Choi
Endocrinology and Metabolism.2025; 40(5): 668. CrossRef
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
Life.2023; 13(4): 1012. CrossRef
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
Ruili Yin, Yongsong Xu, Xin Wang, Longyan Yang, Dong Zhao
Molecules.2022; 27(10): 3055. CrossRef

Metabolic Risk/Epidemiology
Sex Differences in the Effects of CDKAL1 Variants on Glycemic Control in Diabetic Patients: Findings from the Korean Genome and Epidemiology Study: Hye Ah Lee, Hyesook Park, Young Sun Hong; Diabetes Metab J. 2022;46(6):879-889. Published online February 8, 2022; DOI: https://doi.org/10.4093/dmj.2021.0265

65,856 View
202 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Using long-term data from the Korean Genome and Epidemiology Study, we defined poor glycemic control and investigated possible risk factors, including variants related to type 2 diabetes mellitus (T2DM). In addition, we evaluated interaction effects among risk factors for poor glycemic control.
Methods
Among 436 subjects with newly diagnosed diabetes, poor glycemic control was defined based on glycosylated hemoglobin trajectory patterns by group-based trajectory modeling. For the variants related to T2DM, genetic risk scores (GRSs) were calculated and divided into quartiles. Risk factors for poor glycemic control were assessed using a logistic regression model.
Results
Of the subjects, 43% were in the poor-glycemic-control group. Body mass index (BMI) and triglyceride (TG) were associated with poor glycemic control. The risk for poor glycemic control increased by 11.0% per 1 kg/m² increase in BMI and by 3.0% per 10 mg/dL increase in TG. The risk for GRS with poor glycemic control was sex-dependent (P_interaction=0.07), and a relationship by GRS quartiles was found in females but not in males. Moreover, the interaction effect was found to be significant on both additive and multiplicative scales. The interaction effect was evident in the variants of cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like (CDKAL1).
Conclusion
Females with risk alleles of variants in CDKAL1 associated with T2DM had a higher risk for poor glycemic control than males.

Citations

Citations to this article as recorded by

Sex‐ and age‐specific determinants of diabetes: Insights from BKMR and cox modelling of metabolic and lifestyle risk factors in a Korean cohort
Hye Ah Lee
Diabetes, Obesity and Metabolism.2025; 27(9): 5247. CrossRef
Hepatic Cdkal1 deletion regulates HDL catabolism and promotes reverse cholesterol transport
Dan Bi An, Soo-jin Ann, Seungmin Seok, Yura Kang, Sang-Hak Lee
Atherosclerosis.2023; 375: 21. CrossRef

Drug/Regimen
Comparison of Prevailing Insulin Regimens at Different Time Periods in Hospitalized Patients: A Real-World Experience from a Tertiary Hospital: Sun Joon Moon, Hun Jee Choe, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho; Diabetes Metab J. 2022;46(3):439-450. Published online October 20, 2021; DOI: https://doi.org/10.4093/dmj.2021.0065

66,008 View
340 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Prevailing insulin regimens for glycemic control in hospitalized patients have changed over time. We aimed to determine whether the current basal-bolus insulin (BBI) regimen is superior to the previous insulin regimen, mainly comprising split-mixed insulin therapy.
Methods
This was a single tertiary center, retrospective observational study that included non-critically ill patients with type 2 diabetes mellitus who were treated with split-mixed insulin regimens from 2004 to 2007 (period 1) and with BBI from 2008 to 2018 (period 2). Patients from each period were analyzed after propensity score matching. The mean difference in glucose levels and the achievement of fasting and preprandial glycemic targets by day 6 of admission were assessed. The total daily insulin dose, incidence of hypoglycemia, and length of hospital stay were also evaluated.
Results
Among 244 patients from each period, both fasting glucose (estimated mean±standard error, 147.4±3.1 mg/dL vs. 129.4±3.2 mg/dL, P<0.001, day 6) and preprandial glucose (177.7±2.8 mg/dL vs. 152.8±2.8 mg/dL, P<0.001, day 6) were lower in period 2 than in period 1. By day 6 of hospital admission, 42.6% and 67.2% of patients achieved a preprandial glycemic target of <140 mg/dL in periods 1 and 2, respectively (relative risk, 2.00; 95% confidence interval, 1.54 to 2.59), without an increased incidence of hypoglycemia. Length of stay was shorter in period 2 (10.23±0.26 days vs. 8.70±0.26 days, P<0.001).
Conclusion
BBI improved glycemic control in a more efficacious manner than a split-mixed insulin regimen without increasing the risk of hypoglycemia in a hospital setting.

Citations

Citations to this article as recorded by

Premixed insulin: Advantages, disadvantages, and future
Yan Xia, Yun Hu, Jian-Hua Ma
World Journal of Diabetes.2025;[Epub] CrossRef
In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec
Subhash Kumar Wangnoo, Manash P. Baruah, Sailesh Lodha, Debmalya Sanyal, Ramesh Goyal, Basavaraj G. Sooragonda, Sruti Chandrasekaran, G. Vijay Kumar
Diabetes Therapy.2025; 16(4): 547. CrossRef

Short Communication

Type 1 Diabetes
Real-World Analysis of Therapeutic Outcome in Type 1 Diabetes Mellitus at a Tertiary Care Center: Antonia Kietaibl, Michaela Riedl, Latife Bozkurt; Diabetes Metab J. 2022;46(1):149-153. Published online July 6, 2021; DOI: https://doi.org/10.4093/dmj.2020.0267

8,051 View
168 Download
1 Web of Science
1 Crossref

Abstract PDF PubReader ePub

Insulin replacement in type 1 diabetes mellitus (T1DM) needs intensified treatment, which can either be performed by multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). This retrospective analysis of a real-world scenario aimed to evaluate whether glycaemic and cardiovascular risk factors could be controlled with CSII outclass MDI as suggested by recent evidence. Data from patients with either insulin pump (n=68) or injection (n=224) therapy at an Austrian tertiary care centre were analysed between January 2016 and December 2017. There were no significant differences with regard to the latest glycosylated hemoglobin, cardiovascular risk factor control or diabetes-associated late complications. Hypoglycaemia was less frequent (P<0.001), sensor-augmented therapy was more common (P=0.003) and mean body mass index (BMI) was higher (P=0.002) with CSII treatment. This retrospective analysis of real-world data in T1DM did not demonstrate the superiority of insulin pump treatment with regard to glycaemic control or cardiovascular risk factor control.

Citations

Citations to this article as recorded by

Islet Tissue Macrophages in Immunity Homeostasis and Type 1 Diabetes
Yan Wang, Zhaoran Wang, Wenya Diao, Tong Shi, Jiahe Xu, Tiantian Deng, Chaoying Wen, Jienan Gu, Tingting Deng, Sixuan Wang, Cheng Xiao
Clinical Reviews in Allergy & Immunology.2025;[Epub] CrossRef

Reviews

Type 1 Diabetes
Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis: Xiaoling Cai, Chu Lin, Wenjia Yang, Lin Nie, Linong Ji; Diabetes Metab J. 2021;45(3):312-325. Published online March 15, 2021; DOI: https://doi.org/10.4093/dmj.2020.0171

11,151 View
338 Download
10 Web of Science
8 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

In order to evaluate the efficacy and side effects of the non-insulin antidiabetes medications as an adjunct treatment in type 1 diabetes mellitus (T1DM), we conducted systematic searches in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials published between the date of inception and March 2020 to produce a systematic review and meta-analysis. Overall, 57 studies were included. Compared with placebo, antidiabetes agents in adjunct to insulin treatment resulted in significant reduction in glycosylated hemoglobin (weighted mean difference [WMD], –0.30%; 95% confidence interval [CI], –0.34 to –0.25%; P<0.01) and body weight (WMD, –2.15 kg; 95% CI, –2.77 to –1.53 kg; P<0.01), and required a significantly lower dosage of insulin (WMD, –5.17 unit/day; 95% CI, –6.77 to –3.57 unit/day; P<0.01). Compared with placebo, antidiabetes agents in adjunct to insulin treatment increased the risk of hypoglycemia (relative risk [RR], 1.04; 95% CI, 1.01 to 1.08; P=0.02) and gastrointestinal side effects (RR, 1.99; 95% CI, 1.61 to 2.46; P<0.01) in patients with T1DM. Compared with placebo, the use of non-insulin antidiabetes agents in addition to insulin could lead to glycemic improvement, weight control and lower insulin dosage, while they might be associated with increased risks of hypoglycemia and gastrointestinal side effects in patients with T1DM.

Citations

Citations to this article as recorded by

A Retrospective Analysis of the Clinical Characteristics and Treatment Patterns Among Individuals with Diabetes Receiving Insulin Therapy in Japan: The Insulin JP2DB Study
Michiaki Fukui, Satoshi Tsuboi, Yuiko Yamamoto, Yasuo Terauchi
Diabetes Therapy.2026; 17(3): 411. CrossRef
Glycemic Management Across the Lifespan for People With Type 1 Diabetes: A Clinical Practice Guideline
Ilana J. Halperin, Brandy Wicklow, Shazhan Amed, Alanna Chambers, Charlotte Courage, Elizabeth Cummings, Patricia Kirkland, Dylan MacKay, Meranda Nakhla, Zubin Punthakee, Paul M. Ryan, Lindsay Sawatsky, Peter A. Senior, Bikrampal S. Sidhu, Alanna Weisman
Canadian Journal of Diabetes.2025; 49(1): 5. CrossRef
Comparative efficacy and safety of oral hypoglycaemic drugs as adjunctive therapy in the management of type 1 diabetes mellitus: A systematic review and meta‐analysis
Dong Wu, Xiaowu Wang, Qiao Liu, Xia Luo
Diabetes, Obesity and Metabolism.2025; 27(8): 4354. CrossRef
Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists
Patrice Forner, Jennifer Snaith, Jerry R. Greenfield
Internal Medicine Journal.2024; 54(5): 779. CrossRef
Dioscin: Therapeutic potential for diabetes and complications
Haoyang Gao, Ze Wang, Danlin Zhu, Linlin Zhao, Weihua Xiao
Biomedicine & Pharmacotherapy.2024; 170: 116051. CrossRef
The Impact of Body Mass Index, Residual Beta Cell Function and Estimated Glucose Disposal Rate on the Development of Double Diabetes and Microvascular Complications in Patients With Type 1 Diabetes Mellitus
Rameez Raja Bhagadurshah, Subbiah Eagappan, Raghavan Kasthuri Santharam, Sridhar Subbiah
Cureus.2023;[Epub] CrossRef
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Bruce A. Perkins, Jennifer L. Sherr, Chantal Mathieu
Science.2021; 373(6554): 522. CrossRef
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Sun Joon Moon, Inha Jung, Cheol-Young Park
Diabetes & Metabolism Journal.2021; 45(6): 813. CrossRef

Clinical Diabetes & Therapeutics
The Effectiveness of Green Tea or Green Tea Extract on Insulin Resistance and Glycemic Control in Type 2 Diabetes Mellitus: A Meta-Analysis: Jinyue Yu, Peige Song, Rachel Perry, Chris Penfold, Ashley R. Cooper; Diabetes Metab J. 2017;41(4):251-262. Published online August 22, 2017; DOI: https://doi.org/10.4093/dmj.2017.41.4.251

24,867 View
198 Download
63 Web of Science
66 Crossref

Abstract PDF PubReader ePub

Green tea or green tea extract (GT/GTE) has been demonstrated to reduce insulin resistance and improve glycemic control. However, evidence for this health beneficial effect is inconsistent. This systematic review evaluated the effect of GT/GTE on insulin resistance and glycemic control in people with pre-diabetes/type 2 diabetes mellitus (T2DM). Ovid MEDLINE, Embase, AMED, Web of Science, and the Cochrane Library were searched up to April 2017 for randomised controlled trials of participants with pre-diabetes or T2DM, where the intervention was GT/GTE. Meta-analysis was performed to assess the standardised mean difference (SMD) in biomarkers of insulin resistance and glycemic control between GT/GTE and placebo groups. Six studies (n=382) were pooled into random-effects meta-analysis. Overall, no differences were found between GT/GTE and the placebo for glycosylated hemoglobin (HbA1c: SMD, −0.32; 95% confidence interval [CI], −0.86 to 0.23), homeostatic model assessment for insulin resistance (HOMA-IR: SMD, 0.10; 95% CI, −0.17 to 0.38), fasting insulin (SMD, −0.25; 95% CI, −0.64 to 0.15), and fasting glucose (SMD, −0.10; 95% CI, −0.50 to 0.30). No evidence support the consumption of GT/GTE could reduce the levels of HbA1c, HOMA-IR, fasting insulin, or fasting glucose in people with pre-diabetes/T2DM. However, the studies included were small and of varying quality.

Citations

Citations to this article as recorded by

Identification of green tea varieties and origins based on fused surface enhanced Raman spectra from different extraction solvent
Su-Ming Dai, Yu Shen, Jing-Xiang Wang, Xin-Xin Zhang, Yao-Yao Zhang, Ya-Ying Huang, Ri-Hui Su, Jun Yan
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2026; 348: 127220. CrossRef
Harnessing Phytochemicals and Nanotechnology Synergy for Molecular, Epigenetic, and Microbiota-Driven Regulation in Type 2 Diabetes Mellitus
Gagan Prakash, Anis Ahmad Chaudhary, Ruchita Tanu, Mohamed A. M. Ali, Fehmi Boufahja, Pushpender K. Sharma, Sudarshan Singh Lakhawat, Tejpal Yadav, Navneet Kumar Upadhyay, Vikram Kumar
Pharmaceutics.2026; 18(1): 113. CrossRef
Mechanisms of green tea-induced attenuation of osteoporosis and skeletal muscle atrophy: current status and future study recommendations for clinical application
Youngjoo Kwon
Critical Reviews in Food Science and Nutrition.2026; : 1. CrossRef
Green Tea Catechin Plus Inulin Improves Insulin Resistance Without Reducing Visceral Fat and Shows Exploratory Gut Microbiota Signals in Adults with Visceral Obesity: A Double-Blind Randomized Controlled Trial
Chikara Iino, Keita Mikami, Keisuke Furusawa, Satoshi Sato, Kenta Yoshida, Tohru Yamaguchi, Hiroto Bushita, Keita Kinoshita, Yuji Matsui, Seiya Imoto, Takuro Iwane, Yoshinori Tamada, Koichi Murashita, Shigeyuki Nakaji, Tatsuya Mikami, Hirotake Sakuraba
Nutrients.2026; 18(5): 851. CrossRef
Understanding the role of green tea and matcha consumption in cardiovascular health, obesity, and diabetes: Insights from a Saudi Arabian population
Faisal Alsenani, Nasser Alotaiq, Doni Dermawan, Nasr Eldin Elwali, Mohammed Z. Nasrullah, Rashed H. Almalki, Nahar T. Alfarsi, Alwaleed S. Almatrafi, Muhannad S. Alsulami
Human Nutrition & Metabolism.2025; 40: 200302. CrossRef
The effect of green tea supplementation on body composition, muscle damage, and maximal oxygen consumption: a systematic review and meta-analysis of clinical trials
Nastaran Mahmoudi Shirkoohi, Haniyeh Lorzadeh Amin, Salih M. S. Zebari, Fatemeh Naeini, Parisa Karimi, Sakineh Shab-Bidar, Kurosh Djafarian
Sport Sciences for Health.2025; 21(4): 2407. CrossRef
Matcha Green Tea Improves Cafeteria-Diet-Induced NAFLD by Modulating the Gut Microbiota in Rats
Ho-Ching Chong, Shu-Ting Tang, Yu-Chieh Tseng, Suh-Ching Yang, Yasuo Watanabe, Shizuo Yamada, Yu-Chen S. H. Yang, Ya-Ling Chen
Nutrients.2025; 17(19): 3051. CrossRef
Beneficial health effects and possible health concerns of tea consumption: a review
Mingchuan Yang, Li Zhou, Zhipeng Kan, Zhoupin Fu, Xiangchun Zhang, Chung S. Yang
Beverage Plant Research.2025;[Epub] CrossRef
Acute Effect of Black Tea, Green Tea, and Coffee on Blood Pressure and Blood Glucose in Healthy Female Subjects
Esther Oluwasola Aluko, Ezekiel Etim Ben, Grace Edet Bassy
Cardiovascular & Hematological Agents in Medicinal Chemistry.2025; 23(4): 276. CrossRef
Mechanistic Insights into Antioxidant Interventions Targeting Obesity-Induced Oxidative Stress in the Pathogenesis and Complications of Type 2 Diabetes Mellitus
Fani-Niki Varra, Panagiotis Theodosis-Nobelos, Viktoria-Konstantina Varra, Michail Varras
Current Issues in Molecular Biology.2025; 47(12): 1063. CrossRef
Quercetin and Catechin Modulate Alloxan-Induced Nephrotoxicity in Mice by Affecting Oxidative Stress, Inflammation and COX-2 Protein Expression
Amir Hossein Rastineh, Maryam Khamisi Pour, Ali Vadizadeh, Masoud Mahdavinia, Fereshtesadat Fakhredini, Mahdieh Sadat Badiee
Jundishapur Journal of Natural Pharmaceutical Products.2025;[Epub] CrossRef
Is breakfast consumption detrimental, unnecessary, or an opportunity for health promotion? A review of cardiometabolic outcomes and functional food choices
Heitor O. Santos, Grant M. Tinsley
Diabetes/Metabolism Research and Reviews.2024;[Epub] CrossRef
The effect of green tea supplementation on the anthropometric outcomes in overweight and obese women: a time and dose-response meta-analysis of randomized controlled trials
Yiyi Zhang, Nie Tang, Wei Xia, Shaikh Sanjid Seraj, Marcos Pereira, Periyannan Velu, Hui Zhou, Hanshu Yang, Guanggang Du
Critical Reviews in Food Science and Nutrition.2024; 64(28): 10138. CrossRef
A comparison of the effects of green tea and cocoa on glycaemic control and insulin sensitivity in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Hind Mesfer S. Alkhudaydi, Jeremy P.E. Spencer
Nutrition and Healthy Aging.2024; 9(1): 17. CrossRef
Association between green tea intake and digestive system cancer risk in European and East Asian populations: a Mendelian randomization study
Duorui Nie, Xiaoyu He, Hao Zheng, Deyu Deng, Fanghui He, Ruyi Li, Xiaoting Ni, Shunxiang Li, Fei Xu
European Journal of Nutrition.2024; 63(4): 1103. CrossRef
From Gut to Glucose: A Comprehensive Review on Functional Foods and Dietary Interventions for Diabetes Management
Nirali Patel, Susha Dinesh, Sameer Sharma
Current Diabetes Reviews.2024;[Epub] CrossRef
Anti-atherogenic role of green tea (Camellia sinensis) in South Indian smokers
Venkateswarlu Reddy Kanu, Swetha Pulakuntla, Gouthami Kuruvalli, Sree Latha Aramgam, Shakeela Begum Marthadu, Padmavathi Pannuru, Ananda Vardhan Hebbani, Padma Priya Dharmavaram Desai, Kameswara Rao Badri, Damodara Reddy Vaddi
Journal of Ethnopharmacology.2024; 332: 118298. CrossRef
A novel green tea extract-loaded nanofiber coating for kiwi fruit: Improved microbial stability and nutritional quality
Aslıhan Alav, Nazan Kutlu, Erol Kına, Raciye Meral
Food Bioscience.2024; 62: 105043. CrossRef
From a Cup of Tea to Cardiovascular Care: Vascular Mechanisms of Action
Marios Sagris, Panayotis K. Vlachakis, Spyridon Simantiris, Panagiotis Theofilis, Maria Gerogianni, Paschalis Karakasis, Konstantinos Tsioufis, Dimitris Tousoulis
Life.2024; 14(9): 1168. CrossRef
How to better consider and understand interindividual variability in response to polyphenols in clinical trials
Christine Morand
Frontiers in Nutrition.2024;[Epub] CrossRef
Gut microbiota as a driver of the interindividual variability of cardiometabolic effects from tea polyphenols
Qiqiong Li, Tom Van de Wiele
Critical Reviews in Food Science and Nutrition.2023; 63(11): 1500. CrossRef
Recent insights on tea metabolites, their biosynthesis and chemo-preventing effects: A review
Ramkumar Samynathan, Muthu Thiruvengadam, Shivraj Hariram Nile, Mohammad Ali Shariati, Maksim Rebezov, Raghvendra Kumar Mishra, Baskar Venkidasamy, Sureshkumar Periyasamy, Ill-Min Chung, Mirian Pateiro, José M. Lorenzo
Critical Reviews in Food Science and Nutrition.2023; 63(18): 3130. CrossRef
Tea's anti‐obesity properties, cardiometabolic health‐promoting potentials, bioactive compounds, and adverse effects: A review focusing on white and green teas
Behnaz Abiri, Shirin Amini, Mahdi Hejazi, Farhad Hosseinpanah, Afshin Zarghi, Faeze Abbaspour, Majid Valizadeh
Food Science & Nutrition.2023; 11(10): 5818. CrossRef
An investigation into the potential action of polyphenols against human Islet Amyloid Polypeptide aggregation in type 2 diabetes
Anns Mahboob, Degiri Kalana Lasanga Senevirathne, Pradipta Paul, Faisal Nabi, Rizwan Hasan Khan, Ali Chaari
International Journal of Biological Macromolecules.2023; 225: 318. CrossRef
Association between green tea consumption and metabolic syndrome among Korean adults: results from the Health Examinees study
Hyeonjin Cho, Sunwoo Han, Jiwon Jeong, Hyein Jung, Sangah Shin
Journal of Nutrition and Health.2023; 56(1): 70. CrossRef
Relevance of Indian traditional tisanes in the management of type 2 diabetes mellitus: A review
Devi Datt Joshi, Lokesh Deb, Bharat G. Somkuwar, Virendra Singh Rana
Saudi Pharmaceutical Journal.2023; 31(5): 626. CrossRef
Evaluation the Effect of Chronic Obestatin Therapy on the Serum Glucose, Insulin And Lipid Levels in Type 2 Diabetic Rats
Safa Al-Halbouni, Shadi Homsi, Nabil koshji
The Open Public Health Journal.2023;[Epub] CrossRef
Supplementation with a New Standardized Extract of Green and Black Tea Exerts Antiadipogenic Effects and Prevents Insulin Resistance in Mice with Metabolic Syndrome
Mario De la Fuente-Muñoz, María De la Fuente-Fernández, Marta Román-Carmena, Sara Amor, María C. Iglesias-de la Cruz, Guillermo García-Laínez, Silvia Llopis, Patricia Martorell, David Verdú, Eva Serna, Ángel L. García-Villalón, Sonia I. Guilera, Antonio M
International Journal of Molecular Sciences.2023; 24(10): 8521. CrossRef
Ampelopsis grossedentata improves type 2 diabetes mellitus through modulating the gut microbiota and bile acid metabolism
Yu-li Hu, Mei Li, Lei Ding, Chuan Peng, You Wu, Wei Liu, Dan Zhao, Ling-ling Qin, Xiang-yu Guo, Li-li Wu, Tong-hua Liu
Journal of Functional Foods.2023; 107: 105622. CrossRef
Green Tea and Decaffeinated Light Roasted Green Coffee Extract Combination Improved Cardiac Insulin Resistance through Free Fatty Acids and Adiponectin/FAS Pathways Amelioration in Metabolic Syndrome Rat Model
Mifetika Lukitasari, Mohammad Saifur Rohman, Dwi Adi Nugroho, Mukhamad Nur Kholis, Nila Aisyah Wahyuni, Nashi Widodo
F1000Research.2023; 10: 990. CrossRef
Impact of Polyphenols on Inflammatory and Oxidative Stress Factors in Diabetes Mellitus: Nutritional Antioxidants and Their Application in Improving Antidiabetic Therapy
Michal Krawczyk, Izabela Burzynska-Pedziwiatr, Lucyna A. Wozniak, Malgorzata Bukowiecka-Matusiak
Biomolecules.2023; 13(9): 1402. CrossRef
Research progress on the antidiabetic activities of tea and its bioactive components
Jianjian Gao, Dan Chen, Zhiyuan Lin, Jiakun Peng, Shuai Yu, Chuang Zhou, Huimin Jiang, Ruofan Sun, Zhi Lin, Weidong Dai
Beverage Plant Research.2023;[Epub] CrossRef
Identifying Glucose Metabolism Status in Nondiabetic Japanese Adults Using Machine Learning Model with Simple Questionnaire
Tomoki Uchida, Takeshi Kanamori, Takanori Teramoto, Yuji Nonaka, Hiroki Tanaka, Satoshi Nakamura, Norihito Murayama, Rajesh Kaluri
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Potential Bioactive Components and Health Promotional Benefits of Tea ( Camellia sinensis )
Saptadip Samanta
Journal of the American Nutrition Association.2022; 41(1): 65. CrossRef
A Mendelian Randomization Study of the Effect of Tea Intake on Type 2 Diabetes
Yanan Zhang, Ruiqing Wang, Xinhua Tang, Yanjun Wang, Ping Guo, Shukang Wang, Jing Liu
Frontiers in Genetics.2022;[Epub] CrossRef
Dietary Supplements for Weight Management: A Narrative Review of Safety and Metabolic Health Benefits
Eunice Mah, Oliver Chen, DeAnn J. Liska, Jeffrey B. Blumberg
Nutrients.2022; 14(9): 1787. CrossRef
Antioxidative, Anti-Inflammatory, Anti-Obesogenic, and Antidiabetic Properties of Tea Polyphenols—The Positive Impact of Regular Tea Consumption as an Element of Prophylaxis and Pharmacotherapy Support in Endometrial Cancer
Piotr Olcha, Anna Winiarska-Mieczan, Małgorzata Kwiecień, Łukasz Nowakowski, Andrzej Miturski, Andrzej Semczuk, Bożena Kiczorowska, Krzysztof Gałczyński
International Journal of Molecular Sciences.2022; 23(12): 6703. CrossRef
Herbal tea, a novel adjuvant therapy for treating type 2 diabetes mellitus: A review
Xiangyuan Zhang, Lili Zhang, Boxun Zhang, Ke Liu, Jun Sun, Qingwei Li, Linhua Zhao
Frontiers in Pharmacology.2022;[Epub] CrossRef
Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence
Sarah Krull Abe, Manami Inoue
European Journal of Clinical Nutrition.2021; 75(6): 865. CrossRef
Green and white teas as health-promoting foods
Daniel Hinojosa-Nogueira, Sergio Pérez-Burillo, Silvia Pastoriza de la Cueva, José Ángel Rufián-Henares
Food & Function.2021; 12(9): 3799. CrossRef
A systematic review and meta-analysis of association between brain-derived neurotrophic factor and type 2 diabetes and glycemic profile
Milad Davarpanah, Nafiseh Shokri-mashhadi, Rahele Ziaei, Parvane Saneei
Scientific Reports.2021;[Epub] CrossRef
Maltodextrin encapsulation improves thermal and pH stability of green tea extract catechins
Aimara V. De La Cruz‐Molina, Jesus F. Ayala Zavala, Ariadna T. Bernal Mercado, Manuel R. Cruz Valenzuela, Gustavo A. González‐Aguilar, Jaime Lizardi‐Mendoza, Francisco Brown‐Bojorquez, Brenda A. Silva‐Espinoza
Journal of Food Processing and Preservation.2021;[Epub] CrossRef
Camellia sinensis in Dentistry: Technological Prospection and Scientific Evidence
Lídia Audrey Rocha Valadas, Rosueti Diógenes de Oliveira Filho, Edilson Martins Rodrigues Neto, Mary Anne Medeiros Bandeira, Marta Maria de França Fonteles, Vanara Florêncio Passos, Ana Cristina de Mello Fiallos, Mara Assef Leitao Lotif, Nara Juliana Cust
Evidence-Based Complementary and Alternative Medicine.2021; 2021: 1. CrossRef
A comprehensive insight into effects of green tea extract in polycystic ovary syndrome: a systematic review
Vahid Maleki, Ehsaneh Taheri, Parisa Varshosaz, Fatemeh Pourteymour Fard Tabrizi, Jalal Moludi, Hamed Jafari-Vayghan, Mahdi Shadnoush, Seyed Hossein Yahyazadeh Jabbari, Mehri Seifoleslami, Mohammad Alizadeh
Reproductive Biology and Endocrinology.2021;[Epub] CrossRef
Green Tea and Decaffeinated Light Roasted Green Coffee Extract Combination Improved Cardiac Insulin Resistance through Free Fatty Acids and Adiponectin/FAS Pathway Amelioration in Metabolic Syndrome Rat Model
Mifetika Lukitasari, Mohammad Saifur Rohman, Dwi Adi Nugroho, Mukhamad Nur Kholis, Nila Aisyah Wahyuni, Nashi Widodo
F1000Research.2021; 10: 990. CrossRef
Mechanisms Underlying the Antidiabetic Activities of Polyphenolic Compounds: A Review
Tina Nie, Garth J. S. Cooper
Frontiers in Pharmacology.2021;[Epub] CrossRef
Green tea and selenium-enriched green tea ameliorates non-alcoholic fatty liver disease through peripheral 5-hydroxytryptamine signals in high-fat diet-fed mice
Lin Zhang, Jia-Ying Xu, Ya-Fang Du, Zhang-Min Wang, Jian-Xiang Li, N. Ou-Yang, Yan Wang, Xue-Bin Yin, Li-Qiang Qin
International Food Research Journal.2021; 28(5): 996. CrossRef
Green Tea Consumption May Be Associated with Cardiovascular Disease Risk and Nonalcoholic Fatty Liver Disease in Type 2 Diabetics: A Cross-Sectional Study in Southeast China
Huan-Huan Yang, Hui Zhou, Wan-Zhan Zhu, Cai-Long Chen, Guo-Chong Chen, Lu-Gang Yu, Li-Qiang Qin
Journal of Medicinal Food.2020; 23(10): 1120. CrossRef
The effect of green coffee extract supplementation on lipid profile: A systematic review of clinical trial and in-vivo studies
Omid Nikpayam, Amir Hossein Faghfouri, Omid Mohammad Tavakoli-Rouzbehani, Seyyed-Mostafa Jalali, Marziyeh Najafi, Golbon Sohrab
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(5): 1521. CrossRef
Biological fates of tea polyphenols and their interactions with microbiota in the gastrointestinal tract: implications on health effects
Tingting Chen, Chung S. Yang
Critical Reviews in Food Science and Nutrition.2020; 60(16): 2691. CrossRef
Effects of Timing of Acute and Consecutive Catechin Ingestion on Postprandial Glucose Metabolism in Mice and Humans
Masaki Takahashi, Mamiho Ozaki, Miku Tsubosaka, Hyeon-Ki Kim, Hiroyuki Sasaki, Yuji Matsui, Masanobu Hibi, Noriko Osaki, Masashi Miyashita, Shigenobu Shibata
Nutrients.2020; 12(2): 565. CrossRef
Green tea (Camellia sinensis) for the prevention of cancer
Tommaso Filippini, Marcella Malavolti, Francesca Borrelli, Angelo A Izzo, Susan J Fairweather-Tait, Markus Horneber, Marco Vinceti
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef
Metabolic Impact of Flavonoids Consumption in Obesity: From Central to Peripheral
Viviana Sandoval, Hèctor Sanz-Lamora, Giselle Arias, Pedro F. Marrero, Diego Haro, Joana Relat
Nutrients.2020; 12(8): 2393. CrossRef
Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate
Amir M. Al Hroob, Mohammad H. Abukhalil, Omnia E. Hussein, Ayman M. Mahmoud
Biomedicine & Pharmacotherapy.2019; 109: 2155. CrossRef
Effects and Mechanisms of Tea for the Prevention and Management of Diabetes Mellitus and Diabetic Complications: An Updated Review
Jin-Ming Meng, Shi-Yu Cao, Xin-Lin Wei, Ren-You Gan, Yuan-Feng Wang, Shu-Xian Cai, Xiao-Yu Xu, Pang-Zhen Zhang, Hua-Bin Li
Antioxidants.2019; 8(6): 170. CrossRef
Improvement in fasting blood sugar, anthropometric measurement and hs-CRP after consumption of epigallocatechin-3-gallate (EGCG) in patients with type 2 diabetes mellitus
Said Hadi, Meysam Alipour, Vahideh Aghamohammadi, Sahar Shahemi, Fatemeh Ghafouri-Taleghani, Niloufar Pourjavidi, Mona Foroughi, Mackaan Chraqipoor
Nutrition & Food Science .2019; 50(2): 348. CrossRef
The Phosphorylation of IRS1S307 and AktS473 Molecules in Insulin‐Resistant C2C12 Cells Induced with Palmitate Is Influenced by Epigallocatechin Gallate from Green Tea
Salar Bakhtiyari, Motahareh Zaherara, Karimeh Haghani, Mehrdad Khatami, Ali Rashidinejad
Lipids.2019; 54(2-3): 141. CrossRef
Effect of annatto-extracted tocotrienols and green tea polyphenols on glucose homeostasis and skeletal muscle metabolism in obese male mice
Eunhee Chung, Salvatore N. Campise, Hayli E. Joiner, Michael D. Tomison, Gurvinder Kaur, Jannette M. Dufour, Lillian Cole, Latha Ramalingam, Naima Moustaid-Moussa, Chwan-Li Shen
The Journal of Nutritional Biochemistry.2019; 67: 36. CrossRef
Studies on the Prevention of Cancer and Cardiometabolic Diseases by Tea: Issues on Mechanisms, Effective Doses, and Toxicities
Chung S. Yang, Jinsong Zhang
Journal of Agricultural and Food Chemistry.2019; 67(19): 5446. CrossRef
Salvianolic acid B plays an anti-obesity role in high fat diet-induced obese mice by regulating the expression of mRNA, circRNA, and lncRNA
Tian An, Jing Zhang, Bohan Lv, Yufei Liu, Jiangpinghao Huang, Juan Lian, Yanxiang Wu, Sihua Gao, Guangjian Jiang
PeerJ.2019; 7: e6506. CrossRef
Popular functional foods and herbs for the management of type-2-diabetes mellitus: A comprehensive review with special reference to clinical trials and its proposed mechanism
Kamesh Venkatakrishnan, Hui-Fang Chiu, Chin-Kun Wang
Journal of Functional Foods.2019; 57: 425. CrossRef
Green Tea Polyphenols Modify the Gut Microbiome in db/db Mice as Co‐Abundance Groups Correlating with the Blood Glucose Lowering Effect
Tingting Chen, Anna B. Liu, Shili Sun, Nadim J. Ajami, Matthew C. Ross, Hong Wang, Le Zhang, Kenneth Reuhl, Koichi Kobayashi, Janet C. Onishi, Liping Zhao, Chung S. Yang
Molecular Nutrition & Food Research.2019;[Epub] CrossRef
Effect of herbal tea on glycemic control in patients with type 2 diabetes
Boxun Zhang, Rensong Yue, Xiaoying Huang, Ying Wang, Yayi Jiang, Jiawei Chin
Medicine.2019; 98(50): e18346. CrossRef
Effects of polysaccharides and polyphenolics fractions of Zijuan tea (Camellia sinensis var. kitamura) on α‐glucosidase activity and blood glucose level and glucose tolerance of hyperglycaemic mice
Dejing Chen, Jingyuan Sun, Weixue Dong, Yixiao Shen, Zhimin Xu
International Journal of Food Science & Technology.2018; 53(10): 2335. CrossRef
Green tea consumption reduces apelin and orexin-A in overweight and obese women with different training modalities
Rahman Soori, Azadeh Safei, Parisa Pournemati, Amine Ghram
Sport Sciences for Health.2018; 14(2): 421. CrossRef
Green tea consumption and risk of type 2 diabetes in Chinese adults: the Shanghai Women’s Health Study and the Shanghai Men’s Health Study
Xiaona Liu, Wanghong Xu, Hui Cai, Yu-Tang Gao, Honglan Li, Bu-Tian Ji, Xiang Shu, Thomas Wang, Robert E Gerszten, Wei Zheng, Yong-Bing Xiang, Xiao-Ou Shu
International Journal of Epidemiology.2018; 47(6): 1887. CrossRef

Original Article

Clinical Diabetes & Therapeutics
Determinants of Long-Term Durable Glycemic Control in New-Onset Type 2 Diabetes Mellitus: Kyoung Jin Kim, Ju Hee Choi, Kyeong Jin Kim, Jee Hyun An, Hee Young Kim, Sin Gon Kim, Nam Hoon Kim; Diabetes Metab J. 2017;41(4):284-295. Published online August 3, 2017; DOI: https://doi.org/10.4093/dmj.2017.41.4.284

8,231 View
107 Download
13 Web of Science
13 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Long-term durable glycemic control is a difficult goal in the management of type 2 diabetes mellitus (T2DM). We evaluated the factors associated with durable glycemic control in a real clinical setting.

Methods

We retrospectively reviewed the medical records of 194 new-onset, drug-naïve patients with T2DM who were diagnosed between January 2011 and March 2013, and were followed up for >2 years. Glycemic durability was defined as the maintenance of optimal glycemic control (glycosylated hemoglobin [HbA1c] <7.0%) for 2 years without substitution or adding other glucose-lowering agents. Clinical factors and glycemic markers associated with glycemic durability were compared between two groups: a durability group and a non-durability group.

Results

Patients in the durability group had a higher baseline body mass index (26.1 kg/m² vs. 24.9 kg/m²) and lower HbA1c (8.6% vs. 9.7%) than the non-durability group. The initial choice of glucose-lowering agents was similar in both groups, except for insulin and sulfonylureas, which were more frequently prescribed in the non-durability group. In multiple logistic regression analyses, higher levels of education, physical activity, and homeostasis model assessment of β-cell function (HOMA-β) were associated with glycemic durability. Notably, lower HbA1c (<7.0%) at baseline and first follow-up were significantly associated with glycemic durability (adjusted odds ratio [OR], 7.48; 95% confidence interval [CI], 2.51 to 22.3) (adjusted OR, 9.27; 95% CI, 1.62 to 53.1, respectively), after adjusting for confounding variables including the types of glucose-lowering agents.

Conclusion

Early achievement of HbA1c level within the glycemic target was a determinant of long-term glycemic durability in new-onset T2DM, as were higher levels of education, physical activity, and HOMA-β.

Citations

Citations to this article as recorded by

Improving outcomes with early and intensive metabolic control in patients with type 2 diabetes: a long-term modeling analysis of clinical and cost outcomes in Italy
Pierluca Arietti, Kristina Secnik Boye, Maurizio Guidi, Jonathan Rachman, Marco Orsini Federici, Rosanna Raiola, Arianna Avitabile, William J. Valentine
Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Access, awareness, and risk: drivers of unsafe sharps disposal and needle reuse in insulin-treated adults in China
Shaoping Wu, Fang Wang
Frontiers in Public Health.2025;[Epub] CrossRef
Initial Combination Therapy in Type 2 Diabetes
Ji Yoon Kim, Nam Hoon Kim
Endocrinology and Metabolism.2024; 39(1): 23. CrossRef
Validation of RSSDI therapeutic wheel with clinical experience of Indian physicians
Dhruvi Hasnani, Vipul Chavda, Dinesh Agrawal, Bijay Patni, Ashwin David, Sachin Gathe, Rajeev Chawla, Jothydev Kesavadev, Sunil Gupta, Shriji Hasnani, Banshi Saboo
International Journal of Diabetes in Developing Countries.2022; 42(3): 451. CrossRef
Greater Glycemic Burden Is Associated with Further Poorer Glycemic Control in Newly-Diagnosed Type 2 Diabetes Mellitus Patients
Wei-Lun Wen, Hui-Chun Huang, Hsiu-Chu Lin, Wan-Ching Lo, Szu-Chia Chen, Mei-Yueh Lee
Nutrients.2022; 14(2): 320. CrossRef
Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
Hwi Seung Kim, Yun Kyung Cho, Myung Jin Kim, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Frontiers in Endocrinology.2022;[Epub] CrossRef
Durability of glycaemic control in type 2 diabetes: A systematic review and meta‐analysis for its association with body weight changes
Danpei Li, HuaJie Zou, Ping Yin, Wenjun Li, Junyu He, Shuyun Wang, Li Huang, Shiying Shao, Yong Chen, Yan Yang, Xuefeng Yu
Diabetes, Obesity and Metabolism.2021; 23(1): 208. CrossRef
Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective
Linong Ji, Juliana C. N. Chan, Miao Yu, Kun Ho Yoon, Sin Gon Kim, Sung Hee Choi, Chien‐Ning Huang, Shih Te Tu, Chih‐Yuan Wang, Päivi Maria Paldánius, Wayne H. H. Sheu
Diabetes, Obesity and Metabolism.2021; 23(1): 3. CrossRef
Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study
Kyoung Jin Kim, Jimi Choi, Jae Hyun Bae, Kyeong Jin Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim, Nam Hoon Kim
Diabetes & Metabolism Journal.2021; 45(3): 368. CrossRef
Effectiveness of Resistance Training and Associated Program Characteristics in Patients at Risk for Type 2 Diabetes: a Systematic Review and Meta-analysis
Raza Qadir, Nicholas F. Sculthorpe, Taylor Todd, Elise C. Brown
Sports Medicine - Open.2021;[Epub] CrossRef
Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study (Diabetes Metab J 2021;45:368-78)
Ja Young Jeon
Diabetes & Metabolism Journal.2021; 45(4): 613. CrossRef
Association of Habitual Daily Physical Activity With Glucose Tolerance and β-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study
Karla A. Temple, Ashley H. Tjaden, Karen M. Atkinson, Elena Barengolts, Tamara S. Hannon, Kieren J. Mather, Kristina M. Utzschneider, Sharon L. Edelstein, David A. Ehrmann, Babak Mokhlesi, Philip S. Zeitler, Jayne Williams, Melanie Cree-Green, Yesenia Gar
Diabetes Care.2019; 42(8): 1521. CrossRef
Factors Associated with Poor Hemoglobin A1c Control in Patients with Type 2 Diabetes
Salam Alqudah, Anan S. Jarab, Eman A. Alefishat, Fadia Mayyas, Maher Khdour, Sharrel Pinto
Current Diabetes Reviews.2019; 15(2): 164. CrossRef

Review

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea: Seungjoon Oh, Suk Chon, Kyu Jeong Ahn, In-Kyung Jeong, Byung-Joon Kim, Jun Goo Kang; Diabetes Metab J. 2015;39(3):177-187. Published online June 15, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.3.177

8,806 View
63 Download
4 Web of Science
4 Crossref

Abstract PDF PubReader ePub

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between Asian and non-Asian populations. We reviewed available data on GLP-1RAs, focusing on Korean patients, to better understand their risk/benefit profile and help inform local clinical practice. Control of postprandial hyperglycemia is important in Asians in whom the prevalence of post-challenge hyperglycemia is higher (vs. non-Asians). The weight lowering effects of GLP-1RAs are becoming more salient as the prevalence of overweight and obesity among Korean patients increases. The higher rate of gastrointestinal adverse events amongst Asian patients in clinical trials may be caused by higher drug exposure due to the lower body mass index of the participants (vs. non-Asian studies). Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean patients are lacking. Use of GLP-1RAs is appropriate in several patient groups, including patients whose HbA1c is uncontrolled, especially if this is due to postprandial glucose excursions and patients who are overweight or obese due to dietary problems (e.g., appetite control). The potential for gastrointestinal adverse events should be explained to patients at treatment initiation to facilitate the promotion of better compliance.

Citations

Citations to this article as recorded by

Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study
Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park
Diabetes & Metabolism Journal.2024; 48(3): 418. CrossRef
Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Frontiers in Endocrinology.2022;[Epub] CrossRef
Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
Diabetes & Metabolism Journal.2017; 41(5): 337. CrossRef
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
The Korean Journal of Internal Medicine.2017; 32(6): 947. CrossRef

Original Articles

Subjective Assessment of Diabetes Self-Care Correlates with Perceived Glycemic Control but not with Actual Glycemic Control: Jung Hun Ohn, Ju Hee Lee, Eun Shil Hong, Bo Kyung Koo, Sang Wan Kim, Ka Hee Yi, Min Kyong Moon; Diabetes Metab J. 2015;39(1):31-36. Published online February 16, 2015; DOI: https://doi.org/10.4093/dmj.2015.39.1.31

6,836 View
36 Download
1 Web of Science
1 Crossref

Abstract PDF PubReader ePub

Background

We investigated whether patients' perceived glycemic control and self-reported diabetes self-care correlated with their actual glycemic control.

Methods

A survey was administered among patients with diabetes mellitus at an outpatient clinic with structured self-report questionnaires regarding perceived glycemic control and diabetes self-management. Actual glycemic control was defined as a change in glycated hemoglobin (A1C) or fasting plasma glucose (FPG) since the last clinic visit.

Results

Patients who perceived their glycemic control as "improved" actually showed a mild but significant decrease in the mean A1C (-0.1%, P=0.02), and those who perceived glycemic control as "aggravated" had a significant increase in the mean FPG (10.5 mg/dL or 0.59 mmol/L, P=0.04) compared to the "stationary" group. However, one-half of patients falsely predicted their actual glycemic control status. Subjective assessment of diabetes self-care efforts, such as adherence to a diet regimen or physical activity, correlated positively with perceived glycemic control but showed no association with actual glycemic control.

Conclusion

Patients should be encouraged to assess and monitor diabetes self-care more objectively to motivate behavioral modifications and improve their actual glycemic control.

Citations

Citations to this article as recorded by

Social Networking Services-Based Communicative Care for Patients with Diabetes Mellitus in Korea
Hun-Sung Kim, Yoo Jeong, Sun Baik, So Yang, Tong Kim, Hyunah Kim, Hyunyong Lee, Seung-Hwan Lee, Jae Cho, In-Young Choi, Kun-Ho Yoon
Applied Clinical Informatics.2016; 07(03): 899. CrossRef

Current Status of Glycemic Control of Patients with Diabetes in Korea: The Fifth Korea National Health and Nutrition Examination Survey: Ja Young Jeon, Dae Jung Kim, Seung-Hyun Ko, Hyuk-Sang Kwon, Soo Lim, Sung Hee Choi, Chul Sik Kim, Jee Hyun An, Nan Hee Kim, Jong Chul Won, Jae Hyeon Kim, Bong-Yun Cha, Kee-Ho Song; Diabetes Metab J. 2014;38(3):197-203. Published online June 17, 2014; DOI: https://doi.org/10.4093/dmj.2014.38.3.197

9,115 View
65 Download
51 Web of Science
57 Crossref

Abstract PDF PubReader ePub

Background

The Korea National Health and Nutrition Examination Survey (KNHANES) III (2005) reported that 22.9% of individuals with diabetes have a glycated hemoglobin (HbA1c) <6.5% and that 43.5% have an HbA1c <7%. We investigated the levels of glycemic control and the factors associated with glycemic control using data from the KNHANES V (2010 to 2012).

Methods

Subjects with diabetes diagnosed by a physician or those taking antidiabetic medications were classified as individuals with known diabetes. Of 1,498 subjects aged ≥30 years with diabetes, we excluded 157 individuals who were missing HbA1c data. A total of 1,341 subjects were included in the final analysis.

Results

The prevalence of known diabetes was 7.7% (n=1,498, estimated to be 2.32 million people). The proportions of well-controlled diabetes meeting a HbA1c goal of <6.5% and <7% were 27% and 45.6%, respectively. HbA1c increased as the duration of diabetes increased. HbA1c in subjects with a duration of diabetes ≤5 years was lower than in subjects with a duration >5 years. HbA1c in the group taking only oral hypoglycemic agents (OHAs) was significantly lower than that in the group administered only insulin or OHA and insulin in combination. In logistic regression analysis, a longer duration of diabetes, insulin use and the absence of chronic renal failure were associated with HbA1c levels >6.5%.

Conclusion

The level of adequate glycemic control was similar to but slightly improved compared with previous levels. The glycemic control of long-standing diabetes patients is more difficult even though they receive insulin treatment.

Citations

Citations to this article as recorded by

Improved Glycemic Control in Insulin-Treated Individuals With Poorly Controlled Type 2 Diabetes Through Combined Structured Education With Real-Time Continuous Glucose Monitoring
Jee Hee Yoo, Ji Eun Jun, Soo Heon Kwak, Jae Hyeon Kim
Journal of Diabetes Science and Technology.2026; 20(3): 875. CrossRef
Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison
Ji Eun Jun, Seohyun Kim, In‐Kyung Jeong, Jae Hyeon Kim
Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef
Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial
Yong-ho Lee, Kyung Wan Min, Jun Hwa Hong, Soo Lim, Jae Myung Yu, Choon Hee Chung, Jun Sung Moon, Jong Chul Won, Chul Woo Ahn, Jie-Eun Lee, Tae Nyun Kim, Byung-Wan Lee
Diabetes & Metabolism Journal.2026; 50(3): 576. CrossRef
Age-Stratified Trends in Nutrition and Lifestyle Transitions in Korea: Findings from KNHANES 2013–2022
Seongryu Bae, Hyuntae Park
Nutrients.2025; 17(20): 3282. CrossRef
Efficacy and Safety of Stage 5 Connected Insulin Pens in Type 1 or Type 2 Diabetes: Randomized Controlled Trial Protocol
Ji Yoon Kim, Nam Hoon Kim, Soo Heon Kwak, Chang Hee Jung, Eun Seok Kang, Jun Sung Moon, Sun Joon Moon, So Yoon Kwon, Jee Hee Yoo, Younghoon Kim, Tae-min Lee, Chung-il Yang, Jae Hyeon Kim, Sang-Man Jin
Endocrinology and Metabolism.2025;[Epub] CrossRef
Information and Communications Technology–Based Monitoring Service for Tailored Chronic Disease Management in Primary Care: Cost-Effectiveness Analysis Based on ICT-CM Trial Results
Sung-Hee Oh, Jae-Heon Kang, Jin-Won Kwon
Journal of Medical Internet Research.2024; 26: e51239. CrossRef
Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin
Ji Yoon Kim, Sabrina Ilham, Hamza Alshannaq, Richard F. Pollock, Waqas Ahmed, Gregory J. Norman, Sang-Man Jin, Jae Hyeon Kim
Journal of Medical Economics.2024; 27(1): 1245. CrossRef
Socioeconomic inequalities in the prevalence, non-awareness, non-treatment, and non-control of diabetes among South Korean adults in 2021
Seongju Kim, Dong Jun Kim, Hooyeon Lee, Dong Keon Yon
PLOS ONE.2024; 19(11): e0313988. CrossRef
Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study
Sang-Yong Kim, Sungrae Kim
Diabetes Therapy.2023; 14(1): 109. CrossRef
Declined incidence of patients treated for vision-threatening diabetic retinopathy in South Korea: a 12-year nationwide population-based study
Jiwon Kim, Hyojin Seong, Kang Ju Son, Eun Jee Chung
Graefe's Archive for Clinical and Experimental Ophthalmology.2022; 260(1): 101. CrossRef
Glycemic status and general characteristics among individuals with undiagnosed diabetes; findings from second National Diabetes Survey of Pakistan 2016–2017 (NDSP 08)
Abdul Basit, Nazish Waris, Asher Fawwad, Bilal Tahir, Iftikhar Ahmed Siddiqui, Mujeeb Ur Rehman Abro, Khawaja Ishfaq Ahmed, Khurshid Ahmed, Sobia Sabir Ali, Ahmed Bilal, Anam Butt, Bikha Ram Devrajani, Ijaz Hayder, Yasir Humayun, Rabia Irshad, Riasat Ali
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(6): 102535. CrossRef
Glycemic control and its determinants among people with type 2 diabetes mellitus in Ernakulam district, Kerala
ShanaShirin Najeeb, TeenaMary Joy, Aswathy Sreedevi, K Vijayakumar, Syama, . Glycaemic Control and Determinants Team
Indian Journal of Public Health.2022; 66(5): 80. CrossRef
C-peptide level as predictor of type 2 diabetes remission and body composition changes in non-diabetic and diabetic patients after Roux-en-Y gastric bypass
Roberto de Cleva, Flavio Kawamoto, Georgia Borges, Priscila Caproni, Alex Jones Flores Cassenote, Marco Aurelio Santo
Clinics.2021; 76: e2906. CrossRef
Inadequate achievement of ABC goals (HbA1c, blood pressure, LDL-C) among patients with type 2 diabetes in an Iranian population, 2012–2017
Mehrdad Larry, Saeid Alizadeh, Sina Naderi, Bahareh Salekani, Mohammad Ali Mansournia, Soghra Rabizadeh, Alireza Esteghamati, Manouchehr Nakhjavani
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(4): 619. CrossRef
Site-specific cancer risk in patients with type 2 diabetes: a nationwide population-based cohort study in Korea
Suk Kyeong Kim, Ju-Young Jang, Dong-Lim Kim, Young A Rhyu, Suh Eun Lee, Seung-Hyun Ko, Kyungdo Han, Kee-Ho Song
The Korean Journal of Internal Medicine.2020; 35(3): 641. CrossRef
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Mads Frederik Rasmussen
Diabetology International.2020; 11(2): 76. CrossRef
An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men
Seol Ju Moon, Kyung-Sang Yu, Min-Gul Kim
Clinical Therapeutics.2020; 42(6): 1047. CrossRef
Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors
Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam, Eun Seok Kang
Diabetes Care.2019; 42(11): 2057. CrossRef
Factors Influencing Glycemic Control among Type 2 Diabetes Mellitus Patients: The Sixth Korea National Health and Nutrition Examination Survey (2013~2015)
Mee Ock Gu
Korean Journal of Adult Nursing.2019; 31(3): 235. CrossRef
Trends in metabolic risk factors among patients with diabetes mellitus according to income levels: the Korea National Health and Nutrition Examination Surveys 1998 ~ 2014
Sukyung Cho, Kyong Park
Journal of Nutrition and Health.2019; 52(2): 206. CrossRef
Current status of treatment of type 2 diabetes mellitus in Ningbo, China
Tianmeng Yang, Rongjiong Zheng, Qingmei Chen, Yushan Mao
Journal of Clinical Laboratory Analysis.2019;[Epub] CrossRef
Trends in the prevalence and management of diabetes in Korea: 2007-2017
Ji-Yeon Shin
Epidemiology and Health.2019; 41: e2019029. CrossRef
Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status
Bo-Yeon Kim, Jong Chul Won, Jae Hyuk Lee, Hun-Sung Kim, Jung Hwan Park, Kyoung Hwa Ha, Kyu Chang Won, Dae Jung Kim, Kyong Soo Park
Diabetes & Metabolism Journal.2019; 43(4): 487. CrossRef
A new comprehensive diabetes health literacy scale: Development and psychometric evaluation
Eun-Hyun Lee, Young Whee Lee, Kwan-Woo Lee, Moonsuk Nam, So Hun Kim
International Journal of Nursing Studies.2018; 88: 1. CrossRef
Women are less likely than men to achieve optimal glycemic control after 1 year of treatment: A multi-level analysis of a Korean primary care cohort
Seung-Ah Choe, Joo Yeong Kim, Young Sun Ro, Sung-Il Cho, Antonio Palazón-Bru
PLOS ONE.2018; 13(5): e0196719. CrossRef
Ten-Year Mortality Trends for Adults with and without Diabetes Mellitus in South Korea, 2003 to 2013
Kyeong Jin Kim, Tae Yeon Kwon, Sungwook Yu, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Sin Gon Kim, Yousung Park, Nam Hoon Kim
Diabetes & Metabolism Journal.2018; 42(5): 394. CrossRef
Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes
Jong-Dai Kim, Cheol-Young Park, Bong-Yun Cha, Kyu Jeung Ahn, In Joo Kim, Kyong Soo Park, Hyung Woo Lee, Kyung-Wan Min, Jong Chul Won, Min Young Chung, Jae-Taek Kim, Jun Goo Kang, Sung-Woo Park
Clinical Therapeutics.2018; 40(5): 752. CrossRef
Negative Association of Hepatitis B Virus With Hearing Impairment
SKM Azizul Islam, Jin Wook Chung, Young-Sil Lee, HoChan Cho, Seong-Su Moon
American Journal of Audiology.2018; 27(3): 324. CrossRef
The effectiveness, reproducibility, and durability of tailored mobile coaching on diabetes management in policyholders: A randomized, controlled, open-label study
Da Young Lee, Jeongwoon Park, Dooah Choi, Hong-Yup Ahn, Sung-Woo Park, Cheol-Young Park
Scientific Reports.2018;[Epub] CrossRef
Prediction of Type 2 Diabetes Remission after Bariatric or Metabolic Surgery
Ji Yeon Park
Journal of Obesity & Metabolic Syndrome.2018; 27(4): 213. CrossRef
Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis
Seung-Hyun Ko, Kyungdo Han, Yong-ho Lee, Junghyun Noh, Cheol-Young Park, Dae-Jung Kim, Chang Hee Jung, Ki-Up Lee, Kyung-Soo Ko
Diabetes & Metabolism Journal.2018; 42(2): 93. CrossRef
Prediction of Diabetes Remission after Bariatric or Metabolic Surgery
Ji Yeon Park
Journal of Metabolic and Bariatric Surgery.2018; 7(1): 22. CrossRef
Detrimental Effects of Higher Body Mass Index and Smoking Habits on Menstrual Cycles in Korean Women
An Na Jung, Ju Hwan Park, Jihyun Kim, Seok Hyun Kim, Byung Chul Jee, Byung Heun Cha, Jae Woong Sull, Jin Hyun Jun
Journal of Women's Health.2017; 26(1): 83. CrossRef
Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006–2013)
Chang Hee Jung, Jin Ook Chung, Kyungdo Han, Seung-Hyun Ko, Kyung Soo Ko, Joong-Yeol Park
Cardiovascular Diabetology.2017;[Epub] CrossRef
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG‐CoA reductase inhibitors prescribed in Korean patients
Tong Min Kim, Hyunah Kim, Yoo Jin Jeong, Sun Jung Baik, So Jung Yang, Seung‐Hwan Lee, Jae‐Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, In Young Choi, Kun‐Ho Yoon, Hun‐Sung Kim
Pharmacoepidemiology and Drug Safety.2017; 26(10): 1156. CrossRef
Euglycemic Diabetic Ketoacidosis When Reducing Insulin Dosage in Patients Taking Sodium Glucose Cotransporter 2 Inhibitor
Woo Jin Yi, Soo-Kyung Kim, Sun Ung Youn, Namkyu Kang, Myung Won Lee, Seok O Park
The Ewha Medical Journal.2017; 40(1): 55. CrossRef
Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)
Sunghwan Suh, Sun Ok Song, Jae Hyeon Kim, Hyungjin Cho, Woo Je Lee, Byung-Wan Lee
Journal of Diabetes Research.2017; 2017: 1. CrossRef
Prevalence and risk factors for reduced pulmonary function in diabetic patients: The Korea National Health and Nutrition Examination Survey
Hee Yeon Kim, Tae Seo Sohn, Hannah Seok, Chang Dong Yeo, Young Soo Kim, Jae Yen Song, Young Bok Lee, Dong-Hee Lee, Jae-Im Lee, Tae-Kyu Lee, Seong Cheol Jeong, Mihee Hong, Hiun Suk Chae
The Korean Journal of Internal Medicine.2017; 32(4): 682. CrossRef
Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient‐ and physician‐related factors): A prospective observational DIPP‐FACTOR study in Korea
Sin Gon Kim, Nam Hoon Kim, Bon Jeong Ku, Ho Sang Shon, Doo Man Kim, Tae Sun Park, Yong‐Seong Kim, In Joo Kim, Dong Seop Choi
Journal of Diabetes Investigation.2017; 8(3): 346. CrossRef
Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice
You-Cheol Hwang, Ari Kim, Euna Jo, Yeoree Yang, Jae-Hyoung Cho, Byung-Wan Lee
BMC Endocrine Disorders.2017;[Epub] CrossRef
Current status of managing diabetes mellitus in Korea
Kyoung Hwa Ha, Dae Jung Kim
The Korean Journal of Internal Medicine.2016; 31(5): 845. CrossRef
Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002–2013
Seung-Hyun Ko, Dae-Jung Kim, Jong-Heon Park, Cheol-Young Park, Chang Hee Jung, Hyuk-Sang Kwon, Joong-Yeol Park, Kee-Ho Song, Kyungdo Han, Ki-Up Lee, Kyung-Soo Ko
Medicine.2016; 95(27): e4018. CrossRef
A patient-centric approach to optimise insulin therapy in Asia
Su Yen Goh, Ernesto Ang, Shailendra Bajpai, Chaicharn Deerochanawong, Eun-Gyoung Hong, Zanariah Hussein, Shashank Joshi, Nor Azmi Kamaruddin, Sjoberg Kho, Alice Pik-Shan Kong, Chang Yu Pan, Riccardo Perfetti, Apichati Vichayanrat, Aleksandra Vlajnic, Juli
Journal of Diabetes and its Complications.2016; 30(6): 973. CrossRef
Association between blood glucose level derived using the oral glucose tolerance test and glycated hemoglobin level
Hyoung Joo Kim, Young Geon Kim, Jin Soo Park, Young Hwan Ahn, Kyoung Hwa Ha, Dae Jung Kim
The Korean Journal of Internal Medicine.2016; 31(3): 535. CrossRef
Social Networking Services-Based Communicative Care for Patients with Diabetes Mellitus in Korea
Hun-Sung Kim, Yoo Jeong, Sun Baik, So Yang, Tong Kim, Hyunah Kim, Hyunyong Lee, Seung-Hwan Lee, Jae Cho, In-Young Choi, Kun-Ho Yoon
Applied Clinical Informatics.2016; 07(03): 899. CrossRef
Factors Associated with Poor Glycemic Control among Patients with Type 2 Diabetes Mellitus: The Fifth Korea National Health and Nutrition Examination Survey (2010-2012)
Jinhyun Park, Seungji Lim, Eunshil Yim, Youngdae Kim, Woojin Chung
Health Policy and Management.2016; 26(2): 125. CrossRef
Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
Yeoree Yang, Jeong-Ah Shin, Hae Kyung Yang, Seung-Hwan Lee, Seung-Hyun Ko, Yu-Bae Ahn, Kun-Ho Yoon, Jae-Hyoung Cho
Diabetes & Metabolism Journal.2016; 40(6): 454. CrossRef
Health inequalities in hypertension and diabetes management among the poor in urban areas: a population survey analysis in south Korea
Young-Jee Jeon, Chung Reen Kim, Joo-Sung Park, Kyung-Hyun Choi, Myoung Joo Kang, Seung Guk Park, Young-Jin Park
BMC Public Health.2016;[Epub] CrossRef
Prediction of Diabetes Remission in Morbidly Obese Patients After Roux-en-Y Gastric Bypass
Ji Yeon Park, Yong Jin Kim
Obesity Surgery.2016; 26(4): 749. CrossRef
Inhibition of advanced glycation end product formation by burdock root extract
Darye Lee, Choon Young Kim
Journal of Nutrition and Health.2016; 49(4): 233. CrossRef
Diabetes in Asians
Eun-Jung Rhee
Endocrinology and Metabolism.2015; 30(3): 263. CrossRef
Insulin Initiation in Insulin-Naïve Korean Type 2 Diabetic Patients Inadequately Controlled on Oral Antidiabetic Drugs in Real-World Practice: The Modality of Insulin Treatment Evaluation Study
Sang Soo Kim, In Joo Kim, Yong Ki Kim, Kun Ho Yoon, Ho Young Son, Sung Woo Park, Yeon Ah Sung, Hong Sun Baek
Diabetes & Metabolism Journal.2015; 39(6): 481. CrossRef
Current status of glucose, blood pressure and lipid management in type 2 diabetes clinic attendees inIsfahan,Iran
Mohsen Janghorbani, Bahman Papi, Masoud Amini
Journal of Diabetes Investigation.2015; 6(6): 716. CrossRef
Trends in the Diabetes Epidemic in Korea
Kyoung Hwa Ha, Dae Jung Kim
Endocrinology and Metabolism.2015; 30(2): 142. CrossRef
The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor
Won Jin Kim, Sang Soo Kim
The Journal of Korean Diabetes.2014; 15(3): 158. CrossRef
It's Still Not Too Late to Make a Change: Current Status of Glycemic Control in Korea
Sang Yong Kim
Diabetes & Metabolism Journal.2014; 38(3): 194. CrossRef
Association between Diabetes Education Status and Clinical Outcomes of Patients with Diabetes Mellitus: Analysis of the Fifth Korea National Health and Nutrition Examination Survey (KNHANES V)
Jun Sung Kwon, Won Jun Kim, Yang Hee Han, Hyun Joong Kim, Sa Young Shin, Kyoo Ho Choi, Jae Hyuck Jun, Myoung Sook Shim, Jin Yeob Kim
The Journal of Korean Diabetes.2014; 15(4): 236. CrossRef

Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study: Kee-Ho Song, Jung Min Kim, Jung-Hyun Noh, Yongsoo Park, Hyun-Shik Son, Kyong Wan Min, Kyung Soo Ko; Diabetes Metab J. 2013;37(2):117-124. Published online April 16, 2013; DOI: https://doi.org/10.4093/dmj.2013.37.2.117

9,258 View
49 Download
5 Crossref

Abstract PDF PubReader ePub

Background

The purpose of this study was to evaluate change in glycosylated hemoglobin (HbA1c), side effects, and quality of life (QOL) after a 16-week treatment period with Biphasic insulin aspart 30/70 (BIasp30) in patients with type 2 diabetes mellitus (T2DM) who had been suboptimally controlled with oral antidiabetic drugs (OADs).

Methods

The study consisted of a 4-week titration period when concurrent OAD(s) were replaced with BIasp30 and followed by a 12-week maintenance period. All patients completed the Diabetes Treatment Satisfaction Questionnaire at the beginning and the end of the trial. Hypoglycemic episodes were recorded by the patient throughout the trial.

Results

Sixty patients were included, of whom 55 patients (92%) completed the full 16-week treatment period. Seven-point blood glucose was significantly improved as compared with the baseline, except for the postlunch blood glucose level. HbA1c at the end of period was significantly improved from 9.2% to 8.2% (P<0.001). Eleven percent (n=6) of patients achieved HbA1c values ≤6.5% and 22% (n=12) of patients achieved <7.0%. There were 3.4 episodes/patients-year of minor hypoglycemia and 0.05 episodes/patients-year of major hypoglycemia. QOL showed significant changes only in the acceptability of high blood glucose category (P=0.003).

Conclusion

Treatment with once or twice daily BIasp30 may be an option for the patients with T2DM suboptimally controlled with OADs in Korea. However, considering the low number of patients achieving the HbA1c target and the high postlunch blood glucose levels, additional management with another modality may be required for optimal control.

Citations

Citations to this article as recorded by

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
Andreas Liebl, Viswanathan Mohan, Wenying Yang, Krzysztof Strojek, Sultan Linjawi
Drugs in R&D.2018; 18(1): 27. CrossRef
Basal‐prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24‐week randomized non‐inferiority trial
Sang‐Man Jin, Jae Hyeon Kim, Kyung Wan Min, Ji Hyun Lee, Kue Jeong Ahn, Jeong Hyun Park, Hak Chul Jang, Seok Won Park, Kwan Woo Lee, Kyu Chang Won, Young‐Il Kim, Choon Hee Chung, Tae Sun Park, Jee‐Hyun Lee, Moon‐Kyu Lee
Journal of Diabetes.2016; 8(3): 405. CrossRef
The optimal morning:evening ratio in total dose of twice‐daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24‐week multi‐centre prospective, randomized controlled, open‐labelled clinical study
C. H. Jung, J.‐Y. Park, J. H. Cho, K.‐H. Yoon, H. K. Yang, Y.‐H. Lee, B. S. Cha, B.‐W. Lee
Diabetic Medicine.2014; 31(1): 68. CrossRef
Response: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J2013;37:117-24)
Kee-Ho Song, Jung Min Kim, Jung-Hyun Noh, Yongsoo Park, Hyun-Shik Son, Kyong Wan Min, Kyung Soo Ko
Diabetes & Metabolism Journal.2013; 37(3): 214. CrossRef
Letter: Efficacy and Safety of Biphasic Insulin Aspart 30/70 in Type 2 Diabetes Suboptimally Controlled on Oral Antidiabetic Therapy in Korea: A Multicenter, Open-Label, Single-Arm Study (Diabetes Metab J2013;37:117-24)
Byung-Wan Lee
Diabetes & Metabolism Journal.2013; 37(3): 212. CrossRef

The Relationship of Family Support with Blood Glucose Control in Elderly Type 2 Diabetic Patients.: Eun Suk Kim, Seong Jin Lee, Ohk Hyun Ryu, Jee Youn Lee, Hyun Suk Yun, Moon Gi Choi; Korean Diabetes J. 2007;31(5):435-443. Published online September 1, 2007; DOI: https://doi.org/10.4093/jkda.2007.31.5.435

3,611 View
34 Download
7 Crossref

Abstract PDF

BACKGROUND
With the extension of human life span, the prevalence of diabetes in elderly population is increasing. The glycemic control is also important in elderly diabetics because the life expectancy in elderly is steadily increased. In this study, we investigated the role of family support on glycemic control in elderly type diabetic patients. METHODS: This study was conducted with 126 type 2 diabetic patients over 60 years of age who were enrolled between March and December, 2005. The data for glycemic control, family characteristics, and family support were collected by structured questionnaire, personal interview, and medical record review. We used total supportive index scores to evaluate family support. We evaluated the relationship between family support and glycemic control. RESULTS: Fasting plasma glucose was positively correlated with duration of diabetes (r = 0.277, P = 0.003). Postprandial 2 hour plasma glucose was negatively correlated with monthly incomes (r = -0.357, P = 0.002), assessment support (r = -0.201, P = 0.029). Hemoglobin A1c was positively correlated with duration with diabetes (r = 0.294, P = 0.002) and insulin use (r = 0.259, P = 0.004), but it was negatively correlated with diabetic self-management education (r = -0.190, P = 0.036). Adjusted for age, sex, duration of diabetes, and monthly incomes, there were no significant associations between glycemic control and family support. CONCLUSION: In this study, there were no significant associations between glycemic control and family support. More large prospective studies will be followed to exactly evaluate the role of family support in diabetic patients.

Citations

Citations to this article as recorded by

The role of psychological insulin resistance in diabetes self‐care management
Ancho Lim, Youngshin Song
Nursing Open.2020; 7(3): 887. CrossRef
A Predictive Model of Health Outcomes for Young People with Type 2 Diabetes
Sun Young Jung, Sook Ja Lee, Sun Hee Kim, Kyung Mi Jung
Asian Nursing Research.2015; 9(1): 73. CrossRef
Factors Influencing Self-Care Behaviors Related to Insulin Therapy in Elders with Diabetes Mellitus
Na-Yeong Sohn, Jin-Hyang Yang
Journal of Korean Academy of Fundamentals of Nursing.2013; 20(1): 27. CrossRef
Perception of social support by individuals with diabetes mellitus and foot ulcers
Ana Laura Galhardo Figueira, Lílian Cristiane Gomes Villas Boas, Maria Cristina Foss de Freitas, Milton César Foss, Ana Emilia Pace
Acta Paulista de Enfermagem.2012; 25(spe1): 20. CrossRef
The impact of family support on metabolic control in patients with type 2 diabetes
Agata Matej-Butrym, Marek Butrym, Andrzej Jaroszyński
Zdrowie Publiczne.2012; 122(3): 265. CrossRef
Effects of Low Glycemic Index Nutrition Education on the Blood Glucose Control in Patients with Type 2 Diabetes Mellitus
Mi-Ja Kim, Sunja Kwon, Sun Yung Ly
The Korean Journal of Nutrition.2010; 43(1): 46. CrossRef
Relationships of family support, diet therapy practice and blood glucose control in typeII diabetic patients
Jeong-Ok Yun, Ki-Nam Kim
Nutrition Research and Practice.2009; 3(2): 141. CrossRef

The Effects of Lifestyle Modification on the Metabolic Parameters of Type 2 Diabetes.: So Hun Kim, Eun Seok Kang, So Young Park, Suk Jeong Lee, Mi Jin Kim, Ji Soo Yoo, Chul Woo Ahn, Bong Soo Cha, Sung Kil Lim, Hyun Chul Lee; Korean Diabetes J. 2004;28(5):441-451. Published online October 1, 2004

2,137 View
53 Download

Abstract PDF: BACKGROUND
Lifestyle modification is known to have positive effects on glycemic control and improving the cardiovascular risk factors. Although lifestyle modification is considered to be important in treating diabetic patients, there are few studies concerning the direct effect of lifestyle modification on the patients with type 2 diabetes (T2DM). The aim of this study is to evaluate the effects of lifestyle modification on glycemic control, lipid profiles, body indices, serum adiponectin and the hsCRP levels for patients with T2DM in Korea. METHODS: Twenty two patients with T2DM who had no medication changes for the recent 3 months and who also had a HbA1c> or =7.0% were enrolled in a lifestyle modification program. These patients visited Severance Hospital Diabetes Center once every week for 12 weeks, and they were educated about exercise and diet control. Their metabolic and anthropometric parameters were compared with 22 control T2DM patients who were not in the program. RESULTS:Lifestyle modification group patients showed significant decrements in HbA1c (-0.62 +/- 1.29 vs. 0.14 +/- 0.91%, p=0.044), total cholesterol (-0.57 +/- 0.54 vs. -0.06 +/- 0.61 mmol/l, p=0.007), LDL cholesterol (-0.57 +/- 0.62 vs. 0.02 +/- 0.59 mmol/l, p=0.003), body weight (-1.5 +/- 19 vs. 0.2 +/- 1.5 kg, p=0.005) and BMI (-0.6 +/- 0.7 vs 0.0 +/- 0.6 kg/m2, p=0.003) compared with the control subjects. HOMAIR, serum triglyceride, adiponectin, and hsCRP levels showed no significant difference compared to the control subjects. CONCLUSION: Lifestyle modification in Korean T2DM patients had positive effects on weight loss, glycemic control, and lipid profiles. These changes imply that lifestyle modification will be helpful for managing DM and its complications.

Evaluation of Glycemic Control in Type 2 Diabetic Patients have been Treated in General Hospital.: Joung Ho Park, Kwan Woo Kim, Eun Jin Kang, Tak Young Kim, Sa Ra Lee, Su Chan Bae, Mi Kyung Kim, Sin Yeong Choi, Jeong Hyun Park; Korean Diabetes J. 2004;28(3):208-218. Published online June 1, 2004

1,768 View
25 Download

Abstract PDF: BACKGROUND
Good metabolic control is one of the most important parts of managing diabetes. Several studies in western countries have shown glycemic control in type 2 diabetic patients to be poorer than expected. Similar reports in Korea are very limited. Therefore, this study was performed to estimate the degree in glycemic control of type 2 diabetic patients that have been treated in general hospitals in Korea. METHODS: This was a cross-sectional retrospective study conducted on 1012 type 2 diabetic patients treated at the Maryknoll Hospital. Subjects with type 1 diabetes or a treatment duration of less than 6 month were excluded. The glycemic control was estimated by HbA1c and the clinical characteristics, including duration of diabetes, age, height and body weight, checked. The treatment methods were divided into four groups, namely diet, oral hypoglycemic agent, insulin alone, and insulin and oral hypoglycemic agent combination. Data were analyzedsed by SPSS version 11.0. RESULTS: The mean age, BMI, duration of diabetes and HbA1c of the subjects were 61.6+/-9.8 years, 24.6+/-3.2kg/m(2), 12.1+/-6.5 year and 7.6+/-1.3%, respectively, and the percentage of those achieving the goal of glycemic control(HbA1c<7%) was 35.7%. Those who achieved glycemic control were older than those who could not and also had a shorter duration of diabetes(p<0.001). There were no significant differences in the BMI, gender and HbA1c levels before treatment between the four groups. The subjects on diet treatment had a lower mean HbA1c level than those on insulin alone or combined therapy(p<0.05) CONCLUSION: The percentage of type 2 diabetic patients in good glycemic control in our general hospital was less than 40%, which was similar to previous western data. It is our suggestion that a large nationwide study is required to more accurately evaluate the state of glycemic control and find the reasons why certain patients could not reach this goal.

First
Prev
Page of 1
Next
Last

Search